

B. PREVALENCE of reported ESRD therapy

Tables numbered B.22 and higher are not included in the paper edition of the ADR, but are available on the USRDS Web site (<http://www.med.umich.edu/usrds>) and on the USRDS ADR CD.

Prevalence in this section is defined as December 31 Point Prevalence; that is, patients reported as receiving renal replacement therapy for ESRD on December 31 of a given year. The only exception is Table B.3, which shows Annual Period Prevalence counts, or counts of patients reported as receiving renal replacement therapy for ESRD at any time during a calendar year. These definitions exclude:

- persons with acute, as opposed to chronic or end stage, renal failure
- persons with chronic renal failure who die before receiving ESRD treatment
- ESRD treatments which are not reported through HCFA. Most ESRD patients not covered by Medicare were not reported to HCFA prior to 1995. Beginning in 1995, all ESRD patients should have HCFA 2728 "Medical Evidence" forms filed with HCFA and should be included in the database.

Chapter XIII and the *Researcher's Guide* discuss these limitations in more detail.

Since the U.S. population figures used for this report (see Section J) include only residents of the 50 states and the District of Columbia, only these residents are included in the patient counts and rates of this section. The exceptions are the bottom of Table B.1, which reports counts for all ESRD patients, and table B.4 where counts for Puerto Rico and the Territories are reported.

Starting with the 1992 ADR, the methodology for reporting prevalence changed, and patients who we have classified as lost to followup are excluded from these tables. A patient is considered lost to followup during periods of one year or more during which the patient does not have a functioning transplant and has no dialysis bill records. This change results in a decrease on the order of ten percent in the prevalence counts in this ADR compared with those in the 1991 ADR. Beginning with the 1992 ADR, each ADR has calculated prevalence rates for the 10 most recent years using the new methodology and excluding patients designated as lost to followup. Some additional changes were made to the lost to followup methodology for this ADR, as described in Chapter XIII. These changes result in counts of prevalent patients which are about 2 percent higher than with the previous methodology.

Age is computed as age on December 31, except in the period prevalence table, in which age is age on July 1 of the year in question.

Race categories. Race in the USRDS database is categorized as follows:

- Black
- White
- Native American/Alaskan Native

Asian/Pacific Islander
Other
Unknown

The race of each patient is determined by combining the race code reported on the Chronic Renal Disease Medical Evidence Report, HCFA-2728-U4 (HCFA-2728), with the race code recorded in the HCFA Medicare Health Insurance Master file. The resulting race code indicates "Other" or "Unknown" in less than 2 percent of all new cases in recent years.

The Native American/Alaskan Native and the Asian/Pacific Islander race categories were added to the HCFA-2728 in 1981. Counts of new patients for these categories (Reference Tables Section A, pages A.1 and A.3) are significantly under-reported before 1982. In addition, compliance with the requirement to submit the HCFA-2728 improved greatly starting in 1982. As a result of these changes, there is a discontinuity in the coding of race starting in about 1982. The proportion of new patients in the "Other" and "Unknown" race categories drops from about five percent before 1981 to about one percent from 1982 to 1986. The proportion in the "Other" category increases in 1987 and 1988 due to a large increase in the proportion of this category in the Health Insurance Master file, but the combined proportion of "Other" and "Unknown" remains under two percent.

In 1991, the Medicare Health Insurance Master File added the categories of Native American/Alaskan Native, Asian/Pacific Islander, and Hispanic to its race categories for new patients entering the system. This change allows patients for whom there is no Medical Evidence form to be classified as Native American or Asian. However, it also adds Hispanic as a race category, which is inconsistent with the categories on the Medical Evidence Form and those used by the Census Bureau. If a patient is classified as Hispanic in the Health Insurance Master File and has no Medical Evidence Form, then that patient is classified as "Other" race in the USRDS database.

The Census population estimates used in computing prevalence rates use the four race groups of White, Black, Asian and Native American, and all persons are placed in one of these groups. Thus the two percent of patients in the USRDS database with race coded "Other" or "Unknown" do not have a corresponding Census population base for computation of rates. This means that all prevalence rates involving race will be slightly low.

With the incidence tables presented in Section A, the problem of the discontinuity in the coding of race affects only years before 1982 (shown in 1993 and earlier ADR's). With prevalence, this problem continues after 1982 because patients who entered the system before 1982 continue to be prevalent in later years. The problem decreases with each year as the number of patients from earlier years become a smaller and smaller proportion of the total. There is a corresponding problem with primary disease because of the large proportion of incident cases with missing primary disease before 1982.

In summary, there are two distinct problems with race data. The first is the discontinuity in the coding of race before and after 1982. This results in a lack of comparability before and after 1982. The second is that the patients with race "Other" and "Unknown" (under two percent in recent years) have no corresponding category in the Census population data used as the

denominator in computing and adjusting rates. This results in a downward bias in the rates by race.

Treatment of race in reference tables. The discontinuity in the coding of race and the lack of Census population counts corresponding to the "Other" and "Unknown" categories complicates the computation and presentation of rates of ESRD prevalence per million population. The tables in this section follow the scheme used in Section A for incidence, with some modifications.

Table B.1 presents counts of December 31 point prevalent patients by age, race, sex, and primary disease by year. It shows all of the race categories, including "Other" and "Unknown". Table B.2 presents counts of patients lost to followup and Table B.3 presents counts of annual period prevalent patients in the same format. In all three tables, the counts of patients by race and by primary disease must be treated with caution because of the problems described above. The biases are greatest before 1982 and decline with each year after 1982.

Table B.5 presents unadjusted December 31 point prevalence rates per million population by age, race, sex, and primary disease. Rates by race are presented by Black, White, Native American and Asian. The warnings about race and primary disease presented above apply to these tables too.

In those tables from B.8 through B.14 and B.22 through B.27 that report point prevalence rates by race or adjusted for race, we exclude the roughly two percent of patients with race "Other" or "Unknown". This means that all rates will be slightly low in these tables. In order to quantify the effects of this procedure, Table B.6 shows the number of patients remaining after the "Other" and "Unknown" race patients are excluded and Table B.7 shows the percentage of patients excluded. Both tables show the same age, sex, and primary disease categories used in Table B.1.

The percentage excluded figures in Table B.7 help to identify any biases which may be introduced by this procedure. Note that patients with disease Missing are disproportionately represented among those excluded. These are patients for whom a HCFA-2728 was not received. The effect on the unadjusted rates per million of excluding the patients with race "Other" and "Unknown" can be seen by comparing the crude rates from Tables B.5 and B.8.

Table B.8 corresponds to Table B.5 but shows rates adjusted for age, race, and sex. All four race groups are used in the rate adjustment process. Chapter XIII describes the adjustment process.

Tables B.15 through B.21 show December 31 point prevalence counts and adjusted rates by state and ESRD Network including all race groups. Rates are adjusted for race using three race groups, White and Black, and Other.

Population bases for rates. Rates are computed using U.S. resident population on December 31 of each year, which are derived by taking the midpoint between the July 1 estimates published by the Bureau of the Census. Adjustment of rates uses December 31, 1996, U.S. resident population by age, race, and sex as the standard population. See Chapter XIII for a discussion of the database and of the methodologies used.

Below is an explanation of one of the more complex table formats used in this section:

**Specific Rates By Sex By Race By Age
And Rates Adjusted for Age, Race, and Sex**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	
0-4	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
5-9	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
10-14	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
15-19	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
20-24	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
25-29	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
30-34	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
35-39	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
40-44	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
45-49	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
50-54	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
55-59	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
60-64	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
65-69	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
70-74	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
75-79	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
80-84	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
85 plus	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
All Age	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D
Age Adj	E	E	E	E	E	E	E	E	F	F	F	F	G	G	H

- A Specific rates by age by race by sex, with no adjustment.
- B Rates for age by race groups, adjusted for sex.
- C Rates for age by sex groups, adjusted for race.
- D Rates for age groups, adjusted for race and sex.
- E Rates for sex by race groups, adjusted for age.
- F Rates for race groups, adjusted for age and sex.
- G Rates for sex groups, adjusted for age and race.
- H Overall rate adjusted for age, race, and sex.

Standard error tables show the standard errors of the adjusted rates in the corresponding cells of the rates table.

Table B.1
December 31 Point Prevalence Counts of Reported ESRD Therapy
by Year, Age, Race, Sex, and Primary Disease Causing ESRD for U.S. Residents
by Year and Region for All ESRD Patients,
and by Year for All ESRD Patients Lost to Followup

AGE AT ESRD										
0- 4	278	285	280	297	316	335	352	384	437	410
5- 9	513	575	630	665	651	679	702	752	761	850
10- 14	914	958	1034	1070	1132	1195	1288	1396	1458	1447
15- 19	2034	2144	2129	2138	2181	2266	2437	2603	2706	2773
20- 24	4025	4141	4339	4557	4786	4895	5017	5109	5150	5076
25- 29	7181	7633	8023	8185	8371	8470	8733	9132	9490	9616
30- 34	9882	10764	11428	12298	12900	13600	14316	14873	15010	14939
35- 39	11729	12813	13981	14985	16227	17136	18435	19518	20474	20879
40- 44	11435	13132	14967	16675	18131	19514	20910	22962	24383	25508
45- 49	11267	12801	13943	15949	17852	19899	22490	25420	27708	28816
50- 54	11812	13196	14545	15828	17844	19709	22203	24408	26940	29160
55- 59	12874	14132	15540	17165	18857	20482	22634	24976	27107	29310
60- 64	14769	16322	17935	19502	21010	22327	24256	26875	28874	30579
65- 69	14643	16824	18828	20746	23039	25074	27259	29226	31007	32617
70- 74	11067	12938	15078	17599	19869	22018	24654	26557	28321	30580
75- 79	7679	9038	10219	11829	13440	14716	16701	18731	20802	23199
80- 84	3559	4298	5184	5989	7087	8069	9199	10238	11240	12599
85 plus	1245	1552	1942	2367	2782	3269	3741	4318	4970	5725
	136906	153546	170025	187844	206475	223653	245327	267478	286838	304083
RACE										
White	89408	99507	109721	120588	131431	141169	153341	165165	175724	186341
Black	41087	46862	52222	58087	64668	70668	78208	85794	92304	97503
Asian	3935	4329	4853	5526	6205	7119	8247	9463	10277	10795
Native Amer.	1580	1890	2164	2450	2844	3119	3522	4059	4542	4614
Other	638	618	660	703	744	866	1134	2061	3112	3941
Unknown	258	340	405	490	583	712	875	936	879	889
	136906	153546	170025	187844	206475	223653	245327	267478	286838	304083
SEX										
Male	73780	82569	91600	101379	111307	120773	132346	144119	155147	165176
Female	63126	70977	78425	86465	95168	102880	112981	123359	131691	138907
	136906	153546	170025	187844	206475	223653	245327	267478	286838	304083
PRIMARY DIAGNOSIS										
Diabetes	30485	36480	42838	50051	57513	63946	73221	83729	92972	100892
Hypertension	32064	36880	41725	46921	52728	57294	63658	67458	70464	72961
Glomeruloneph.	28756	31442	33974	36532	39048	41533	44668	47900	50594	52229
Cystic Kidney	7687	8295	8950	9710	10477	11166	12010	12884	13497	13992
Other Urologic	2615	2875	3140	3479	3834	4107	4494	5090	5675	6093
Other Cause	17184	18938	20363	22033	23733	25204	27244	30389	32482	33919
Unknown Cause	9747	9985	10390	11048	11747	12272	13007	13390	13827	14103
Missing Cause	8368	8651	8645	8070	7395	8131	7025	6638	7327	9894
	136906	153546	170025	187844	206475	223653	245327	267478	286838	304083
U. S.										
U. S.	136695	152864	169145	186723	205087	221889	242377	264140	283887	300092
Presumed U. S.	211	682	880	1121	1388	1764	2950	3338	2951	3991
Puerto Rico	1611	1823	2026	2187	2427	2586	2841	3017	3238	3434
Other non-U. S.	138	167	206	228	255	273	306	348	396	450
	138655	155536	172257	190259	209157	226512	248474	270843	290472	307967
Lost to Followup	9105	8477	8821	9698	10632	11331	12281	13609	17329	22264

Patients alive on ESRD therapy and not lost to followup on December 31 of each year
 (with exception of last row detailing Lost to Followup).

Includes Medicare patients only.

Age is as of December 31.

Table B.2
Counts of U.S. Patients Lost to Followup on December 31
by Year, Age, Race, Sex, and Primary Disease Causing ESRD

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
AGE AT ESRD										
0- 4	11	10	15	19	22	17	16	22	29	46
5- 9	31	31	25	25	31	35	42	44	59	72
10- 14	36	28	38	45	53	50	62	53	64	67
15- 19	102	89	81	83	74	88	75	82	105	142
20- 24	169	136	139	151	146	145	152	157	232	322
25- 29	366	319	291	278	271	274	260	295	438	587
30- 34	600	544	527	535	531	508	504	532	655	869
35- 39	749	727	744	796	781	796	776	812	1054	1351
40- 44	734	713	763	830	906	934	1021	1120	1406	1726
45- 49	736	675	676	756	846	902	991	1125	1476	1933
50- 54	687	627	664	728	794	821	864	996	1411	1946
55- 59	810	673	679	764	809	828	935	1043	1352	1943
60- 64	1011	889	895	938	1028	1032	1071	1131	1620	2204
65- 69	1056	951	1003	1079	1216	1299	1424	1515	1877	2402
70- 74	869	867	918	1079	1253	1443	1622	1852	2129	2550
75- 79	641	666	718	828	952	1071	1227	1400	1745	2108
80- 84	344	373	443	519	604	707	795	908	1046	1254
85 plus	153	159	202	245	315	381	444	522	631	742
	9105	8477	8821	9698	10632	11331	12281	13609	17329	22264
RACE										
White	6117	6023	6178	6677	7307	7763	8376	9098	10962	13340
Black	2648	2125	2251	2572	2781	2969	3204	3647	4952	6807
Asian	207	215	249	281	338	388	445	544	845	1173
Native Amer.	76	69	86	103	120	122	135	157	233	301
Other	30	23	26	26	32	27	37	49	81	338
Unknown	27	22	31	39	54	62	84	114	256	305
	9105	8477	8821	9698	10632	11331	12281	13609	17329	22264
SEX										
Male	5395	5176	5370	5812	6291	6699	7151	7823	9641	12046
Female	3710	3301	3451	3886	4341	4632	5130	5786	7688	10218
	9105	8477	8821	9698	10632	11331	12281	13609	17329	22264
PRIMARY DIAGNOSIS										
Diabetes	1076	1034	1100	1322	1557	1784	2094	2488	3643	5379
Hypertension	2033	1869	1988	2265	2584	2795	3084	3465	4540	5693
Glomeruloneph.	2136	2035	2063	2157	2238	2297	2345	2517	3012	3672
Cystic Kidney	354	289	283	276	296	301	323	339	446	567
Other Urologic	175	170	171	202	181	206	231	267	334	431
Other Cause	1419	1368	1493	1647	1816	1954	2140	2330	2915	3807
Unknown Cause	1096	1023	1041	1068	1120	1113	1160	1237	1455	1651
Missing Cause	816	689	682	761	840	881	904	966	984	1064
	9105	8477	8821	9698	10632	11331	12281	13609	17329	22264

Patients lost to followup on December 31 of each year.
Includes Medicare patients only.
Age is as of December 31.

Table B.3
Annual U.S. Period Prevalence Counts of Reported ESRD Therapy
by Year, Age, Race, Sex, and Primary Disease Causing ESRD for U.S. Residents

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
AGE AT ESRD										
0- 4	342	368	351	379	378	399	414	476	525	515
5- 9	558	595	688	689	716	729	781	803	830	875
10- 14	973	1046	1127	1186	1211	1297	1365	1506	1551	1586
15- 19	2264	2400	2420	2366	2426	2453	2628	2827	2987	2985
20- 24	4443	4579	4679	4956	5192	5394	5542	5699	5651	5586
25- 29	7870	8366	8797	8971	9205	9299	9589	9857	10275	10413
30- 34	10717	11593	12382	13255	14016	14685	15529	16302	16480	16409
35- 39	12686	13819	14942	16102	17500	18616	19877	21236	22279	22697
40- 44	12199	14025	16072	18211	19602	21102	22724	24760	26483	27730
45- 49	12424	14044	15389	17002	19590	21550	24349	27513	30623	31651
50- 54	13400	14891	16444	17748	19708	21853	24692	27386	29446	32616
55- 59	15390	16742	18053	19833	21882	23709	26190	28791	31155	33283
60- 64	18100	19855	21720	23629	25404	27053	29254	32076	34434	36605
65- 69	18605	21379	23891	26369	29016	31497	34223	36593	38764	40986
70- 74	14745	16929	19550	22567	25876	28737	31905	34607	37008	39851
75- 79	10497	12377	14037	15911	18271	20165	22264	25078	27857	31066
80- 84	5020	6096	7134	8386	9719	11169	12767	14229	15835	17766
85 plus	1790	2252	2774	3356	4037	4704	5424	6239	7201	8411
	162023	181356	200450	220916	243749	264411	289517	315978	339384	361031
RACE										
White	106862	118628	130969	143691	157511	169408	183519	197875	210944	224531
Black	47713	54539	60366	66995	74613	81807	90536	99523	107053	113357
Asian	4528	4873	5455	6127	6914	7858	9239	10627	11736	12333
Native Amer.	1834	2170	2513	2831	3280	3623	4072	4689	5296	5401
Other	778	766	710	762	811	941	1229	2260	3421	4442
Unknown	308	380	437	510	620	774	922	1004	934	967
	162023	181356	200450	220916	243749	264411	289517	315978	339384	361031
SEX										
Male	87488	97646	107966	118982	131181	142245	155699	169639	182822	194891
Female	74535	83710	92484	101934	112568	122166	133818	146339	156562	166140
	162023	181356	200450	220916	243749	264411	289517	315978	339384	361031
PRIMARY DIAGNOSIS										
Diabetes	37938	44914	52667	61295	70629	78609	89293	102192	114370	124348
Hypertension	39148	45010	50795	57087	64156	69848	77292	82083	85794	89406
Glomeruloneph.	31856	34722	37476	40032	42845	45431	48802	52402	55460	57326
Cystic Kidney	8423	9057	9760	10484	11310	12096	12923	13937	14611	15148
Other Urologic	3088	3393	3679	4004	4384	4697	5123	5816	6535	6964
Other Cause	19727	21686	23359	25227	27302	28997	31375	35155	38209	39877
Unknown Cause	11681	12022	12251	12914	13880	14379	15019	15617	16143	16545
Missing Cause	10162	10552	10463	9873	9243	10354	9690	8776	8262	11417
	162023	181356	200450	220916	243749	264411	289517	315978	339384	361031

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup at any time during each year. Includes Medicare patients only.

Age is as of July 1.

Table B.4
 December 31, 1997 Point Prevalence Counts of Reported ESRD Therapy
 by Age, Sex, and Primary Disease Causing ESRD
 for Patients Residing Outside 50 States and D.C.

	Puerto Rico	Other non-US
	Count	Count
		%
ALL PATIENTS	3434	450
AGE AT ESRD		
0-19	52	7
20-44	769	95
45-64	1687	227
65-74	637	98
75 plus	289	23
SEX		
Male	2067	235
Female	1367	215
PRIMARY DIAGNOSIS		
Diabetes	1337	197
Hypertension	588	95
Glomeruloneph.	802	63
Cystic Kidney	135	15
Other Urologic	85	11
Other Cause	267	34
Unknown Cause	158	17
Missing Cause	62	18

Patients alive on ESRD therapy and not lost to followup on December 31, 1997. Includes Medicare patients only.
 Age is as of December 31.

Table B.5
December 31 Point Prevalence Rates per Million Population of Reported ESRD Therapy
by Year, Age, Race, Sex, and Primary Disease Causing ESRD
Unadjusted

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
AGE AT ESRD										
0- 4	15	15	15	15	16	17	18	20	23	22
5- 9	29	32	35	36	35	37	37	39	39	43
10- 14	55	56	59	60	62	64	69	74	77	76
15- 19	111	120	122	124	126	129	136	141	144	144
20- 24	207	216	227	238	252	263	275	287	294	290
25- 29	332	357	382	401	421	437	458	481	501	511
30- 34	459	494	519	554	580	613	651	689	714	731
35- 39	610	650	690	720	760	787	833	871	906	921
40- 44	690	756	819	888	954	1003	1046	1118	1156	1178
45- 49	854	940	999	1083	1141	1220	1317	1416	1501	1559
50- 54	1064	1169	1264	1335	1440	1520	1654	1770	1852	1848
55- 59	1211	1345	1487	1642	1782	1895	2055	2225	2345	2452
60- 64	1374	1531	1692	1855	2032	2198	2410	2681	2880	3032
65- 69	1480	1679	1873	2075	2306	2511	2742	2950	3155	3364
70- 74	1409	1625	1853	2106	2326	2538	2808	3017	3234	3509
75- 79	1287	1485	1643	1867	2089	2255	2519	2763	2985	3241
80- 84	946	1108	1300	1466	1691	1877	2086	2269	2443	2690
85 plus	425	516	626	729	826	938	1039	1164	1302	1458
0- 19	53	55	57	57	58	60	64	68	70	71
20- 44	450	487	524	559	596	627	665	707	736	752
45- 64	1111	1225	1332	1439	1543	1640	1776	1919	2027	2093
65- 74	1449	1655	1864	2089	2315	2524	2773	2981	3192	3433
75 plus	986	1148	1303	1477	1666	1821	2025	2219	2406	2633
RACE										
White	432	477	522	569	615	655	706	755	797	839
Black	1373	1544	1694	1850	2026	2180	2379	2576	2737	2854
Other	721	768	824	896	974	1070	1207	1401	1546	1614
SEX										
Male	616	683	749	819	889	954	1035	1116	1190	1255
Female	501	558	610	666	726	777	845	915	968	1012
PRIMARY DIAGNOSIS										
Diabetes	124	147	171	197	224	247	280	317	349	375
Hypertension	131	149	166	185	206	221	243	256	264	271
Glomeruloneph.	117	127	135	144	152	160	171	181	190	194
Cystic Kidney	31	33	36	38	41	43	46	49	51	52
Other Urologic	11	12	13	14	15	16	17	19	21	23
Other Cause	70	76	81	87	93	97	104	115	122	126
Unknown Cause	40	40	41	44	46	47	50	51	52	52
Missing Cause	34	35	34	32	29	31	27	25	28	37
CRUDE RATE	557	619	678	741	805	863	938	1013	1077	1131

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Rates are not reported for some race categories for reasons discussed in notes at beginning of this Section.
 The population base is the U.S. resident population on December 31 of each year.
 Age is as of December 31.
 See Table B. 8 and following for rates adjusted for age, race, and sex.

Table B.6
December 31 Point Prevalence Counts of Reported ESRD Therapy
by Year, Age, Race, Sex, and Primary Disease Causing ESRD
after Dropping Patients with Race "Other" and "Unknown"

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
AGE AT ESRD										
0- 4	276	280	274	288	303	322	337	359	405	378
5- 9	510	569	621	654	631	656	678	722	726	802
10- 14	907	945	1018	1051	1110	1168	1255	1356	1407	1394
15- 19	2011	2121	2099	2105	2145	2218	2386	2541	2629	2679
20- 24	3986	4102	4298	4516	4734	4836	4934	5001	5017	4912
25- 29	7115	7544	7937	8086	8274	8366	8626	9002	9334	9419
30- 34	9775	10652	11306	12171	12759	13441	14134	14647	14732	14639
35- 39	11614	12675	13836	14825	16072	16968	18222	19266	20165	20497
40- 44	11340	13033	14845	16540	17966	19324	20679	22657	24016	25103
45- 49	11173	12706	13828	15813	17709	19732	22285	25117	27337	28342
50- 54	11738	13120	14460	15732	17723	19557	22009	24088	26498	28628
55- 59	12805	14066	15469	17077	18767	20368	22456	24670	26667	28803
60- 64	14710	16261	17864	19430	20931	22229	24118	26616	28459	30038
65- 69	14583	16767	18767	20680	22963	24981	27113	28942	30647	32176
70- 74	11025	12898	15026	17540	19800	21931	24550	26398	28077	30267
75- 79	7650	9013	10199	11807	13417	14683	16643	18625	20633	23001
80- 84	3551	4286	5172	5976	7073	8044	9171	10178	11160	12502
85 plus	1241	1550	1941	2360	2771	3251	3722	4296	4938	5673
	136010	152588	168960	186651	205148	222075	243318	264481	282847	299253
RACE										
White	89408	99507	109721	120588	131431	141169	153341	165165	175724	186341
Black	41087	46862	52222	58087	64668	70668	78208	85794	92304	97503
Asian	3935	4329	4853	5526	6205	7119	8247	9463	10277	10795
Native Amer.	1580	1890	2164	2450	2844	3119	3522	4059	4542	4614
	136010	152588	168960	186651	205148	222075	243318	264481	282847	299253
SEX										
Male	73296	82021	90991	100691	110539	119872	131228	142459	152992	162566
Female	62714	70567	77969	85960	94609	102203	112090	122022	129855	136687
	136010	152588	168960	186651	205148	222075	243318	264481	282847	299253
PRIMARY DIAGNOSIS										
Diabetes	30387	36389	42735	49936	57365	63724	72847	82884	91635	99237
Hypertension	31981	36787	41622	46806	52595	57133	63384	67033	69917	72289
Glomeruloneph.	28552	31225	33740	36283	38791	41251	44327	47401	49961	51501
Cystic kidney	7661	8269	8923	9678	10446	11129	11962	12816	13411	13893
Other Urologic	2608	2868	3132	3468	3823	4092	4469	5051	5617	6028
Other Cause	17106	18860	20281	21942	23635	25092	27082	30136	32156	33524
Unknown Cause	9630	9878	10281	10934	11628	12148	12855	13202	13600	13838
Missing Cause	8085	8312	8246	7604	6865	7506	6392	5958	6550	8943
	136010	152588	168960	186651	205148	222075	243318	264481	282847	299253

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Age is as of December 31.

Table B.7
Percent Decrease in December 31 Point Prevalence Counts of Reported ESRD Therapy
by Year, Age, Race, Sex, and Primary Disease Causing ESRD
after Dropping Patients with Race "Other" and "Unknown"

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
AGE AT ESRD										
0- 4	0.7	1.8	2.1	3.0	4.1	3.9	4.3	6.5	7.3	7.8
5- 9	0.6	1.0	1.4	1.7	3.1	3.4	3.4	4.0	4.6	5.6
10- 14	0.8	1.4	1.5	1.8	1.9	2.3	2.6	2.9	3.5	3.7
15- 19	1.1	1.1	1.4	1.5	1.7	2.1	2.1	2.4	2.8	3.4
20- 24	1.0	0.9	0.9	0.9	1.1	1.2	1.7	2.1	2.6	3.2
25- 29	0.9	1.2	1.1	1.2	1.2	1.2	1.2	1.4	1.6	2.0
30- 34	1.1	1.0	1.1	1.0	1.1	1.2	1.3	1.5	1.9	2.0
35- 39	1.0	1.1	1.0	1.1	1.0	1.0	1.2	1.3	1.5	1.8
40- 44	0.8	0.8	0.8	0.8	0.9	1.0	1.1	1.3	1.5	1.6
45- 49	0.8	0.7	0.8	0.9	0.8	0.8	0.9	1.2	1.3	1.6
50- 54	0.6	0.6	0.6	0.6	0.7	0.8	0.9	1.3	1.6	1.8
55- 59	0.5	0.5	0.5	0.5	0.5	0.6	0.8	1.2	1.6	1.7
60- 64	0.4	0.4	0.4	0.4	0.4	0.4	0.6	1.0	1.4	1.8
65- 69	0.4	0.3	0.3	0.3	0.3	0.4	0.5	1.0	1.2	1.4
70- 74	0.4	0.3	0.3	0.3	0.3	0.4	0.4	0.6	0.9	1.0
75- 79	0.4	0.3	0.2	0.2	0.2	0.2	0.3	0.6	0.8	0.9
80- 84	0.2	0.3	0.2	0.2	0.2	0.3	0.3	0.6	0.7	0.8
85 plus	0.3	0.1	0.1	0.3	0.4	0.6	0.5	0.5	0.6	0.9
	0.7	0.6	0.6	0.6	0.6	0.7	0.8	1.1	1.4	1.6
SEX										
Male	0.7	0.7	0.7	0.7	0.7	0.7	0.8	1.2	1.4	1.6
Female	0.7	0.6	0.6	0.6	0.6	0.7	0.8	1.1	1.4	1.6
	0.7	0.6	0.6	0.6	0.6	0.7	0.8	1.1	1.4	1.6
PRIMARY DIAGNOSIS										
Diabetes	0.3	0.2	0.2	0.2	0.3	0.3	0.5	1.0	1.4	1.6
Hypertension	0.3	0.3	0.2	0.2	0.3	0.3	0.4	0.6	0.8	0.9
Glomeruloneph.	0.7	0.7	0.7	0.7	0.7	0.7	0.8	1.0	1.3	1.4
Cystic Kidney	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.5	0.6	0.7
Other Urologic	0.3	0.2	0.3	0.3	0.3	0.4	0.6	0.8	1.0	1.1
Other Cause	0.5	0.4	0.4	0.4	0.4	0.4	0.6	0.8	1.0	1.2
Unknown Cause	1.2	1.1	1.0	1.0	1.0	1.0	1.2	1.4	1.6	1.9
Missing Cause	3.4	3.9	4.6	5.8	7.2	7.7	9.0	10.2	10.6	9.6
	0.7	0.6	0.6	0.6	0.6	0.7	0.8	1.1	1.4	1.6

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Note that the Missing disease group is disproportionately represented.

Table B.8
December 31 Point Prevalence Rates per Million Population of Reported ESRD Therapy
by Year, Age, Race, Sex, and Primary Disease Causing ESRD
Adjusted for Age, Race, and Sex

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
AGE AT ESRD										
0- 4	15	15	14	15	15	16	17	18	21	19
5- 9	28	31	34	35	34	35	35	37	37	40
10- 14	54	55	58	58	60	62	66	71	73	72
15- 19	109	116	118	120	122	123	129	134	135	135
20- 24	202	211	221	232	244	253	262	271	276	271
25- 29	328	351	375	392	411	425	445	465	482	489
30- 34	456	490	514	549	573	605	640	674	693	706
35- 39	615	653	692	719	758	782	825	860	892	903
40- 44	721	788	849	912	971	1016	1056	1123	1155	1171
45- 49	903	997	1058	1150	1213	1292	1386	1478	1552	1588
50- 54	1140	1252	1352	1425	1540	1632	1776	1892	1981	1988
55- 59	1331	1474	1622	1784	1935	2055	2217	2386	2505	2609
60- 64	1551	1721	1897	2069	2258	2427	2645	2920	3114	3256
65- 69	1702	1928	2143	2363	2610	2834	3066	3265	3464	3659
70- 74	1647	1904	2166	2454	2711	2969	3289	3529	3746	4020
75- 79	1536	1770	1960	2226	2495	2698	3014	3286	3520	3809
80- 84	1186	1390	1638	1848	2145	2359	2625	2847	3051	3317
85 plus	600	725	873	1026	1154	1287	1422	1572	1772	1956
Age Group Summary										
0- 19	51	54	56	57	58	59	62	65	66	66
20- 44	464	498	530	561	592	616	646	679	700	708
45- 64	1231	1361	1482	1607	1737	1851	2006	2169	2288	2360
65- 74	1674	1916	2155	2408	2661	2902	3178	3397	3605	3840
75 plus	1108	1295	1490	1700	1931	2115	2354	2569	2781	3027
RACE										
White	431	474	516	560	603	639	686	730	767	803
Black	1783	2006	2198	2399	2621	2810	3050	3275	3450	3579
Asian	765	798	846	908	970	1067	1185	1307	1357	1369
Native Amer.	1161	1366	1523	1681	1932	2069	2280	2565	2804	2773
SEX										
Male	685	756	826	899	971	1036	1115	1191	1258	1314
Female	492	545	593	643	696	741	800	858	900	931
PRIMARY DIAGNOSIS										
Diabetes	130	153	177	203	229	251	282	316	344	366
Hypertension	140	159	176	194	213	227	247	257	262	266
Glomeruloneph.	121	131	139	147	155	162	172	181	188	190
Cystic Kidney	33	35	37	40	42	44	47	49	50	51
Other Urologi c	11	12	13	14	15	16	17	19	21	22
Other Cause	71	77	82	88	93	98	104	115	121	124
Unknown Cause	41	41	42	44	46	48	50	50	51	51
Missing Cause	34	35	34	31	27	29	25	23	25	33
CRUDE RATE										
	554	615	674	736	800	857	930	1002	1062	1113
ADJUSTED RATE										
	581	642	700	760	821	875	943	1009	1062	1105

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section. All rates are therefore slightly low but are consistently defined and are comparable. The bias introduced by excluding the cases with race "Other" or "Unknown" is unpredictable.

Age is as of December 31 of each year.

The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is the July 1, 1995, U.S. resident population.

Rates by age are adjusted for race and sex.

Rates by sex are adjusted for race and age.

Rates by race are adjusted for sex and age.

Rates by primary disease and "adjusted rate" row are adjusted for age, race, and sex.

The "Crude rate" row is not adjusted.

Table B.9
December 31 Point Prevalence Counts
of Reported ESRD Therapy
by Age, Sex, and Race

1992-1994

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	537	105	*	*	649	255	38	13	*	313	792	143	17	10	962
5- 9	1015	234	33	17	1299	537	103	22	*	666	1552	337	55	21	1965
10- 14	1625	395	55	22	2097	1141	214	65	16	1436	2766	609	120	38	3533
15- 19	2624	902	127	73	3726	2140	697	124	62	3023	4764	1599	251	135	6749
20- 24	5176	2443	299	97	8015	4330	1789	276	94	6489	9506	4232	575	191	14504
25- 29	9294	4197	471	125	14087	7567	3100	385	127	11179	16861	7297	856	252	25266
30- 34	15516	6170	693	264	22643	12114	4780	582	215	17691	27630	10950	1275	479	40334
35- 39	19548	9579	909	316	30352	13679	6179	816	236	20910	33227	15758	1725	552	51262
40- 44	21578	12235	1066	384	35263	14319	7206	918	263	22706	35897	19441	1984	647	57969
45- 49	21591	12376	1031	555	35553	14698	8119	973	383	24173	36289	20495	2004	938	59726
50- 54	20118	11726	1123	608	33575	14703	9558	907	546	25714	34821	21284	2030	1154	59289
55- 59	19727	11612	1074	614	33027	15702	11352	908	602	28564	35429	22964	1982	1216	61591
60- 64	21159	11110	1017	554	33840	18575	13198	958	707	33438	39734	24308	1975	1261	67278
65- 69	24658	10020	1077	438	36193	22450	14491	1218	705	38864	47108	24511	2295	1143	75057
70- 74	23511	7491	973	255	32230	20574	11882	1095	500	34051	44085	19373	2068	755	66281
75- 79	17101	4333	611	170	22215	14113	7439	737	239	22528	31214	11772	1348	409	44743
80- 84	9504	2209	373	69	12155	7900	3720	365	148	12133	17404	5929	738	217	24288
85 plus	3643	886	153	38	4720	3219	1656	120	29	5024	6862	2542	273	67	9744
All Age	237925	108023	11089	4602	361639	188016	105521	10482	4883	308902	425941	213544	21571	9485	670541

1995-1997

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	564	148	24	*	743	306	75	14	*	399	870	223	38	11	1142
5- 9	1121	274	25	14	1434	638	126	35	17	816	1759	400	60	31	2250
10- 14	1900	511	68	31	2510	1260	297	72	18	1647	3160	808	140	49	4157
15- 19	3136	1167	133	53	4489	2329	802	163	66	3360	5465	1969	296	119	7849
20- 24	5115	2663	322	128	8228	4192	2065	333	112	6702	9307	4728	655	240	14930
25- 29	9606	5212	576	175	15569	7568	4006	432	180	12186	17174	9218	1008	355	27755
30- 34	16105	7619	806	250	24780	12345	5923	702	268	19238	28450	13542	1508	518	44018
35- 39	22285	10964	1073	432	34754	15789	7977	1056	352	25174	38074	18941	2129	784	59928
40- 44	26073	15075	1369	590	43107	17251	9749	1282	387	28669	43324	24824	2651	977	71776
45- 49	28131	17560	1477	799	47967	19241	11589	1405	594	32829	47372	29149	2882	1393	80796
50- 54	27065	15825	1587	879	45356	19378	12386	1351	743	33858	46443	28211	2938	1622	79214
55- 59	25940	15359	1616	848	43763	19924	14230	1314	909	36377	45864	29589	2930	1757	80140
60- 64	27070	14362	1546	741	43719	22543	16523	1398	930	41394	49613	30885	2944	1671	85113
65- 69	29934	12691	1488	637	44750	26746	17677	1693	899	47015	56680	30368	3181	1536	91765
70- 74	30051	9616	1444	399	41510	25391	15498	1625	718	43232	55442	25114	3069	1117	84742
75- 79	23845	6013	1064	236	31158	19502	9991	1188	420	31101	43347	16004	2252	656	62259
80- 84	13425	2865	644	89	17023	11007	4966	670	174	16817	24432	7831	1314	263	33840
85 plus	5549	1283	286	39	7157	4905	2514	254	77	7750	10454	3797	540	116	14907
All Age	296915	139207	15548	6347	458017	230315	136394	14987	6868	388564	527230	275601	30535	13215	846581

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 * Values for cells with fewer than 10 patients are suppressed.

Table B.10
December 31 Point Prevalence Rates per Million Population of Reported ESRD Therapy:
Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex

1992-1994

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	22	22	*	*	11	*	11	*	17	15	*	16	22	11	16
5- 9	44	53	32	50	25	24	22	*	34	38	27	31	45	24	35
10- 14	71	91	52	64	53	51	63	48	62	71	57	56	73	53	63
15- 19	121	218	129	247	105	173	131	218	113	195	130	232	134	116	125
20- 24	224	617	252	328	198	439	241	345	211	526	246	337	276	232	253
25- 29	387	1106	407	446	324	748	315	479	355	924	360	463	479	378	427
30- 34	561	1555	571	941	445	1064	451	761	502	1304	509	849	690	526	606
35- 39	716	2534	798	1241	507	1439	659	892	609	1974	726	1061	953	633	788
40- 44	879	3885	1073	1765	583	1975	809	1143	728	2906	936	1444	1274	772	1015
45- 49	1037	5351	1329	3229	695	2945	1106	2113	861	4110	1210	2653	1609	1005	1297
50- 54	1229	6587	1952	4730	866	4384	1446	3926	1042	5453	1689	4314	1961	1357	1649
55- 59	1456	8021	2430	6155	1089	6152	1811	5508	1268	7060	2107	5816	2361	1794	2069
60- 64	1672	8728	2937	7017	1328	7838	2133	7852	1498	8273	2521	7432	2660	2239	2444
65- 69	2054	8733	3862	6989	1557	9339	3183	9401	1801	9035	3502	8212	3008	2670	2837
70- 74	2314	8983	4450	5452	1563	9601	3934	8360	1929	9293	4160	6924	3261	2725	2990
75- 79	2386	7715	4582	5759	1338	7959	4232	5608	1849	7832	4376	5678	3166	2319	2736
80- 84	2276	6939	4719	3898	1044	6022	3867	5209	1644	6462	4265	4563	2965	1811	2376
85 plus	1385	3848	2982	2851	468	2967	1669	1085	915	3392	2287	1929	1764	831	1288
All Age	750	2343	860	1405	571	2065	770	1468	659	2197	814	1437	953	778	863
Age Adj	773	3190	1202	2105	535	2481	968	2071	643	2827	1074	2094	1041	746	880

1995-1997

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	24	33	18	*	14	17	11	*	19	25	14	18	25	14	19
5- 9	47	58	21	41	28	27	31	51	37	42	26	46	47	28	38
10- 14	82	115	58	86	57	69	64	51	69	91	61	68	85	59	72
15- 19	135	261	122	162	107	185	154	206	121	223	138	186	151	120	135
20- 24	235	689	279	447	206	522	292	409	220	604	286	428	296	251	273
25- 29	415	1391	453	592	336	982	313	665	375	1182	381	629	541	420	479
30- 34	620	1945	633	893	483	1339	509	979	550	1636	570	937	791	597	691
35- 39	790	2738	860	1589	568	1764	786	1280	677	2240	822	1430	1046	734	885
40- 44	986	4254	1206	2479	655	2402	1007	1541	817	3307	1104	1999	1420	896	1150
45- 49	1220	6321	1569	4132	825	3509	1291	2916	1018	4880	1428	3511	1903	1199	1539
50- 54	1451	8025	2279	6040	1005	5104	1734	4750	1222	6528	1999	5369	2351	1582	1954
55- 59	1791	9820	3072	7851	1298	7101	2244	7583	1538	8425	2647	7704	2904	2121	2500
60- 64	2177	11166	3816	8832	1655	9639	2814	9715	1911	10383	3302	9279	3433	2778	3097
65- 69	2525	10617	4746	9778	1926	11047	3880	11461	2220	10834	4301	10635	3695	3236	3462
70- 74	2924	11132	5835	7755	1928	12268	4815	11286	2416	11707	5309	9552	4112	3425	3765
75- 79	3060	9774	6630	6945	1764	10190	5408	8821	2394	9975	6005	7896	4069	3024	3538
80- 84	2905	8676	6907	4240	1386	7771	5505	5505	2127	8210	6169	4888	3790	2381	3072
85 plus	1889	5065	4328	2284	660	4099	2650	2179	1258	4563	3450	2237	2378	1180	1767
All Age	913	2897	1086	1849	685	2566	982	1973	797	2723	1032	1911	1171	952	1059
Age Adj	929	3855	1515	2687	635	3033	1209	2709	767	3435	1345	2714	1254	896	1059

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is the July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.11
Standard Errors for Adjusted December 31 Point Prevalence Rates per Million Population
of Reported ESRD Therapy by Sex, Race, and Age,
Adjusted for Age, Race, and Sex

1992-1994

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	1.0	2.2	*	*	0.7	1.3	3.1	*	0.6	1.3	1.8	5.0	0.9	0.6	0.5
5- 9	1.4	3.5	5.5	12.2	1.1	2.4	4.7	*	0.9	2.1	3.6	6.7	1.3	1.0	0.8
10- 14	1.8	4.6	7.0	13.7	1.6	3.5	7.8	12.0	1.2	2.9	5.2	9.1	1.6	1.4	1.1
15- 19	2.4	7.3	11.5	28.9	2.3	6.6	11.8	27.6	1.6	4.9	8.2	20.0	2.2	2.1	1.5
20- 24	3.1	12.5	14.5	33.3	3.0	10.4	14.5	35.5	2.2	8.1	10.3	24.4	3.1	2.9	2.1
25- 29	4.0	17.1	18.7	39.9	3.7	13.4	16.1	42.5	2.7	10.8	12.3	29.2	4.0	3.6	2.7
30- 34	4.5	19.8	21.7	57.9	4.0	15.4	18.7	51.9	3.0	12.5	14.3	38.8	4.6	4.0	3.0
35- 39	5.1	25.9	26.5	69.8	4.3	18.3	23.1	58.1	3.3	15.7	17.5	45.2	5.5	4.4	3.5
40- 44	6.0	35.1	32.9	90.1	4.9	23.3	26.7	70.5	3.8	20.9	21.1	56.8	6.8	5.1	4.2
45- 49	7.1	48.1	41.4	137.1	5.7	32.7	35.5	108.0	4.5	28.8	27.1	86.7	8.6	6.5	5.4
50- 54	8.7	60.8	58.2	191.8	7.1	44.8	48.0	168.0	5.6	37.5	37.6	127.1	10.9	8.5	6.8
55- 59	10.4	74.4	74.2	248.4	8.7	57.7	60.1	224.5	6.7	46.8	47.4	166.9	13.2	10.7	8.4
60- 64	11.5	82.8	92.1	298.1	9.7	68.2	68.9	295.3	7.5	53.4	57.1	209.5	14.8	12.4	9.6
65- 69	13.1	87.2	117.7	334.0	10.4	77.6	91.2	354.0	8.3	58.2	73.8	243.5	16.3	13.8	10.6
70- 74	15.1	103.8	142.7	341.4	10.9	88.1	118.9	373.9	9.2	67.8	92.1	253.3	19.1	15.3	12.2
75- 79	18.2	117.2	185.4	441.7	11.3	92.3	155.9	362.7	10.6	74.2	120.1	284.6	22.5	16.3	13.8
80- 84	23.3	147.6	244.3	469.3	11.7	98.7	202.4	428.2	12.9	88.0	157.7	317.0	28.6	17.9	16.7
85 plus	22.9	129.3	241.1	462.6	8.3	72.9	152.3	201.5	12.0	73.3	140.3	247.3	26.9	12.9	14.6
Age Adj	1.6	10.1	12.3	33.0	1.2	7.7	10.0	30.4	1.0	6.2	7.8	22.3	1.7	1.3	1.1

1995-1997

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	1.0	2.7	3.7	*	0.8	2.0	2.9	*	0.6	1.7	2.3	5.4	0.9	0.7	0.6
5- 9	1.4	3.5	4.1	10.8	1.1	2.4	5.2	12.3	0.9	2.1	3.3	8.2	1.3	1.0	0.8
10- 14	1.9	5.1	7.1	15.4	1.6	4.0	7.6	12.1	1.2	3.2	5.2	9.7	1.7	1.5	1.1
15- 19	2.4	7.7	10.6	22.3	2.2	6.5	12.0	25.4	1.6	5.0	8.0	17.1	2.3	2.1	1.5
20- 24	3.3	13.4	15.6	39.5	3.2	11.5	16.0	38.7	2.3	8.8	11.2	27.6	3.3	3.1	2.2
25- 29	4.2	19.3	18.9	44.7	3.9	15.5	15.1	49.6	2.9	12.3	12.0	33.5	4.3	3.8	2.9
30- 34	4.9	22.3	22.3	56.5	4.3	17.4	19.2	59.8	3.3	14.1	14.7	41.2	5.0	4.3	3.3
35- 39	5.3	26.1	26.3	76.5	4.5	19.7	24.2	68.2	3.5	16.3	17.8	51.1	5.6	4.6	3.6
40- 44	6.1	34.6	32.6	102.1	5.0	24.3	28.1	78.3	3.9	21.0	21.5	64.0	6.9	5.3	4.3
45- 49	7.3	47.7	40.8	146.2	5.9	32.6	34.4	119.7	4.7	28.7	26.7	94.1	8.8	6.6	5.4
50- 54	8.8	63.8	57.2	203.7	7.2	45.9	47.2	174.2	5.7	39.0	37.0	133.5	11.2	8.7	7.0
55- 59	11.1	79.2	76.4	269.6	9.2	59.5	61.9	251.5	7.2	49.2	49.0	184.0	14.1	11.2	8.9
60- 64	13.2	93.2	97.0	324.5	11.0	75.0	75.3	318.6	8.6	59.5	61.1	227.2	16.7	13.7	10.8
65- 69	14.6	94.2	123.0	387.4	11.8	83.1	94.3	382.2	9.3	62.7	77.1	272.1	17.9	15.1	11.7
70- 74	16.9	113.5	153.6	388.2	12.1	98.5	119.4	421.2	10.3	74.9	96.8	286.8	21.1	17.0	13.5
75- 79	19.8	126.0	203.2	452.1	12.6	102.0	156.9	430.4	11.6	80.6	127.9	312.0	24.4	18.0	15.0
80- 84	25.1	162.1	272.2	449.4	13.2	110.3	212.7	417.3	14.0	97.2	171.4	306.6	31.1	19.7	18.2
85 plus	25.4	141.4	255.9	365.7	9.4	81.8	166.3	248.3	13.3	80.7	150.7	221.3	29.3	14.5	16.1
Age Adj	1.7	10.7	13.1	35.5	1.3	8.3	10.3	33.5	1.1	6.7	8.1	24.4	1.9	1.4	1.2

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is the July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.12
December 31 Point Prevalence Counts of Reported ESRD Therapy
by Age, Sex, Race, and Primary Disease Causing ESRD

1994-1997

Diabetes

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	15	10	*	*	31	10	*	*	*	17	25	15	*	*	48
5- 9	*	0	0	0	*	*	*	*	0	10	*	*	*	0	15
10-14	*	*	0	0	*	*	*	0	*	*	*	*	0	*	*
15-19	13	12	*	0	27	21	19	*	0	42	34	31	*	0	69
20-24	195	119	*	*	321	224	182	*	10	422	419	301	*	14	743
25-29	1571	504	25	*	2108	1704	744	26	37	2511	3275	1248	51	45	4619
30-34	5714	1185	81	66	7046	4786	1271	94	91	6242	10500	2456	175	157	13288
35-39	9555	1711	180	132	11578	6560	1742	182	135	8619	16115	3453	362	267	20197
40-44	11356	2861	284	292	14793	7511	2496	176	217	10400	18867	5357	460	509	25193
45-49	12454	4540	427	544	17965	8248	4356	338	421	13363	20702	8896	765	965	31328
50-54	12021	5643	673	673	19010	8507	6553	418	612	16090	20528	12196	1091	1285	35100
55-59	12052	7042	772	728	20594	9972	8797	612	846	20227	22024	15839	1384	1574	40821
60-64	12698	7034	844	662	21238	12859	10806	803	930	25398	25557	17840	1647	1592	46636
65-69	13518	6225	849	528	21120	15389	11834	1066	902	29191	28907	18059	1915	1430	50311
70-74	11425	4407	720	286	16838	13582	9531	1026	667	24806	25007	13938	1746	953	41644
75-79	6764	2343	443	126	9676	8063	5388	640	315	14406	14827	7731	1083	441	24082
80-84	2667	845	222	46	3780	3323	2112	266	128	5829	5990	2957	488	174	9609
85 plus	709	269	90	10	1078	1023	651	105	36	1815	1732	920	195	46	2893
All Age	112733	44751	5617	4109	167210	101787	66496	5762	5348	179393	214520	111247	11379	9457	346603

Hypertension

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	10	11	0	0	21	*	16	0	*	24	16	27	0	*	45
5- 9	19	*	0	0	25	27	*	0	*	33	46	11	0	*	58
10-14	25	*	0	*	33	36	10	0	*	49	61	17	0	*	82
15-19	82	108	0	*	199	108	56	10	*	177	190	164	10	12	376
20-24	401	869	41	15	1326	336	367	27	25	755	737	1236	68	40	2081
25-29	1108	2076	100	30	3314	650	944	43	29	1666	1758	3020	143	59	4980
30-34	1885	3500	174	51	5610	1078	1777	106	16	2977	2963	5277	280	67	8587
35-39	2634	5996	246	82	8958	1366	2962	197	52	4577	4000	8958	443	134	13535
40-44	3409	8933	335	120	12797	1746	4131	265	67	6209	5155	13064	600	187	19006
45-49	4184	10416	342	163	15105	2267	5009	326	79	7681	6451	15425	668	242	22786
50-54	4671	9292	373	156	14492	2802	5184	335	96	8417	7473	14476	708	252	22909
55-59	5295	8343	435	100	14173	3250	5782	323	96	9451	8545	14125	758	196	23624
60-64	6932	7505	419	114	14970	4256	6708	375	97	11436	11188	14213	794	211	26406
65-69	9930	6880	454	107	17371	6550	7611	489	101	14751	16480	14491	943	208	32122
70-74	12690	5451	555	103	18799	8257	7529	487	111	16384	20947	12980	1042	214	35183
75-79	12282	3732	478	62	16554	8393	5522	450	106	14471	20675	9254	928	168	31025
80-84	7964	1994	338	29	10325	6050	3286	339	57	9732	14014	5280	677	86	20057
85 plus	3538	938	155	19	4650	3079	1859	134	39	5111	6617	2797	289	58	9761
All Age	77059	76057	4445	1161	158722	50257	58758	3906	980	113901	127316	134815	8351	2141	272623

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 * Values for cells with fewer than 10 patients are suppressed.

Table B.12(Continued)
December 31 Point Prevalence Counts of Reported ESRD Therapy
by Age, Sex, Race, and Primary Disease Causing ESRD

1994-1997

Glomeruloneph.

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	66	*	*	0	78	71	*	*	*	87	137	16	11	*	165
5- 9	241	60	10	10	321	240	42	17	*	305	481	102	27	16	626
10-14	536	166	28	*	737	490	140	47	*	684	1026	306	75	14	1421
15-19	1099	677	67	25	1868	1040	443	70	49	1602	2139	1120	137	74	3470
20-24	2364	1529	203	53	4149	1943	1079	196	61	3279	4307	2608	399	114	7428
25-29	4364	2389	385	100	7238	3247	1610	269	81	5207	7611	3999	654	181	12445
30-34	6641	2775	543	95	10054	4275	2049	370	110	6804	10916	4824	913	205	16858
35-39	8506	3407	652	179	12744	5005	2301	614	132	8052	13511	5708	1266	311	20796
40-44	9271	4057	767	175	14270	5282	2438	707	108	8535	14553	6495	1474	283	22805
45-49	9143	3757	702	169	13771	5195	2296	629	138	8258	14338	6053	1331	307	22029
50-54	7752	2521	580	145	10998	4478	1615	453	117	6663	12230	4136	1033	262	17661
55-59	6722	1873	487	133	9215	3800	1382	369	81	5632	10522	3255	856	214	14847
60-64	6287	1503	334	77	8201	3582	1241	251	74	5148	9869	2744	585	151	13349
65-69	6202	1118	288	72	7680	3846	1070	261	61	5238	10048	2188	549	133	12918
70-74	5688	829	322	36	6875	3644	923	217	41	4825	9332	1752	539	77	11700
75-79	4090	472	178	51	4791	2701	614	182	35	3532	6791	1086	360	86	8323
80-84	2221	207	103	15	2546	1570	257	95	14	1936	3791	464	198	29	4482
85 plus	847	83	45	*	980	678	179	27	*	887	1525	262	72	*	1867
All Age	82040	27431	5698	1347	116516	51087	19687	4781	1119	76674	133127	47118	10479	2466	193190

Cystic Kidney

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	56	*	0	0	61	53	*	*	0	62	109	10	*	0	123
5- 9	110	24	*	*	142	87	10	*	*	105	197	34	*	*	247
10-14	139	16	*	*	163	119	23	*	0	149	258	39	*	*	312
15-19	156	18	*	*	184	153	33	18	0	204	309	51	25	*	388
20-24	217	25	*	*	254	226	21	*	0	255	443	46	15	*	509
25-29	275	33	15	*	325	270	18	*	*	300	545	51	23	*	625
30-34	374	62	*	10	450	393	73	11	12	489	767	135	15	22	939
35-39	939	134	24	10	1107	695	142	16	12	865	1634	276	40	22	1972
40-44	1956	226	53	26	2261	1167	314	54	13	1548	3123	540	107	39	3809
45-49	3411	418	104	29	3962	2415	417	65	19	2916	5826	835	169	48	6878
50-54	4048	455	114	42	4659	3195	586	72	24	3877	7243	1041	186	66	8536
55-59	3581	416	106	18	4121	3325	456	78	36	3895	6906	872	184	54	8016
60-64	2888	350	76	23	3337	3091	439	63	27	3620	5979	789	139	50	6957
65-69	2278	259	61	10	2608	2766	297	67	16	3146	5044	556	128	26	5754
70-74	1645	167	48	*	1866	1855	231	40	*	2130	3500	398	88	10	3996
75-79	723	98	30	*	855	973	131	25	*	1137	1696	229	55	12	1992
80-84	319	45	*	0	371	359	34	13	0	406	678	79	20	0	777
85 plus	110	21	*	0	134	84	32	*	*	118	194	53	*	*	252
All Age	23225	2772	663	200	26860	21226	3262	554	180	25222	44451	6034	1217	380	52082

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

* Values for cells with fewer than 10 patients are suppressed.

Table B.12(Continued)
December 31 Point Prevalence Counts of Reported ESRD Therapy
by Age, Sex, Race, and Primary Disease Causing ESRD

1994-1997

Other Urologic

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	78	32	*	0	113	13	0	0	0	13	91	32	*	0	126
5- 9	142	39	*	0	186	32	*	0	0	37	174	44	*	0	223
10-14	278	59	15	*	360	110	13	*	*	128	388	72	17	11	488
15-19	412	120	13	*	546	229	19	*	*	254	641	139	17	*	800
20-24	481	92	20	*	602	360	32	*	*	408	841	124	27	18	1010
25-29	748	114	14	13	889	421	61	*	*	497	1169	175	21	21	1386
30-34	742	121	34	15	912	528	44	17	13	602	1270	165	51	28	1514
35-39	687	129	20	13	849	638	50	18	12	718	1325	179	38	25	1567
40-44	714	117	22	*	860	539	97	27	*	665	1253	214	49	*	1525
45-49	594	112	21	*	728	566	83	18	*	670	1160	195	39	*	1398
50-54	472	98	16	10	596	493	97	32	*	626	965	195	48	14	1222
55-59	525	110	27	10	672	481	81	41	*	604	1006	191	68	11	1276
60-64	670	135	33	*	845	492	96	21	*	610	1162	231	54	*	1455
65-69	805	217	28	*	1059	522	111	33	*	670	1327	328	61	13	1729
70-74	1094	202	28	10	1334	486	100	32	*	622	1580	302	60	14	1956
75-79	1084	135	31	10	1260	457	71	16	*	551	1541	206	47	17	1811
80-84	732	120	27	*	888	206	35	14	0	255	938	155	41	*	1143
85 plus	327	64	12	*	411	93	25	*	0	125	420	89	19	*	536
All Age	10585	2016	369	140	13110	6666	1020	296	73	8055	17251	3036	665	213	21165

Other Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	425	103	12	*	544	183	39	*	*	232	608	142	20	*	776
5- 9	767	186	11	*	970	296	85	17	*	406	1063	271	28	14	1376
10-14	1207	311	44	11	1573	655	121	22	*	804	1862	432	66	17	2377
15-19	1780	379	71	29	2259	1103	322	71	32	1528	2883	701	142	61	3787
20-24	2242	532	104	58	2936	1812	754	143	29	2738	4054	1286	247	87	5674
25-29	3070	980	120	45	4215	2611	1318	160	47	4136	5681	2298	280	92	8351
30-34	3949	1388	111	49	5497	3618	1956	210	65	5849	7567	3344	321	114	11346
35-39	4074	1721	104	92	5991	4121	2380	248	61	6810	8195	4101	352	153	12801
40-44	3833	1910	154	57	5954	3772	2156	243	61	6232	7605	4066	397	118	12186
45-49	3385	1544	112	54	5095	3798	1643	264	56	5761	7183	3187	376	110	10856
50-54	3010	1057	84	45	4196	3360	1211	242	47	4860	6370	2268	326	92	9056
55-59	2685	866	99	61	3711	3061	972	126	35	4194	5746	1838	225	96	7905
60-64	2909	775	86	43	3813	3004	923	128	32	4087	5913	1698	214	75	7900
65-69	3439	649	94	37	4219	3485	788	129	47	4449	6924	1437	223	84	8668
70-74	3513	585	75	29	4202	3175	674	127	36	4012	6688	1259	202	65	8214
75-79	2898	413	68	21	3400	2407	422	76	24	2929	5305	835	144	45	6329
80-84	1755	218	38	10	2021	1346	261	38	*	1654	3101	479	76	19	3675
85 plus	747	121	22	*	898	554	156	*	*	723	1301	277	31	12	1621
All Age	45688	13738	1409	659	61494	42361	16181	2261	601	61404	88049	29919	3670	1260	122898

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

* Values for cells with fewer than 10 patients are suppressed.

Table B.12(Continued)
December 31 Point Prevalence Counts of Reported ESRD Therapy
by Age, Sex, Race, and Primary Disease Causing ESRD

1994-1997

Unknown Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	47	*	0	0	55	16	*	0	0	20	63	12	0	0	75
5- 9	99	15	*	0	116	71	*	*	*	80	170	19	*	*	196
10-14	175	58	*	*	238	160	37	*	*	206	335	95	10	*	444
15-19	309	134	13	10	466	282	87	20	*	393	591	221	33	14	859
20-24	673	233	31	18	955	523	182	44	11	760	1196	415	75	29	1715
25-29	1142	480	71	19	1712	778	270	40	12	1100	1920	750	111	31	2812
30-34	1462	552	92	40	2146	1191	372	80	24	1667	2653	924	172	64	3813
35-39	1785	856	139	35	2815	1328	435	68	22	1853	3113	1291	207	57	4668
40-44	1908	924	104	44	2980	1339	516	124	23	2002	3247	1440	228	67	4982
45-49	1703	980	115	36	2834	1278	554	125	20	1977	2981	1534	240	56	4811
50-54	1521	682	119	30	2352	1165	476	119	27	1787	2686	1158	238	57	4139
55-59	1396	584	92	19	2091	1126	526	87	28	1767	2522	1110	179	47	3858
60-64	1552	601	115	23	2291	1159	659	97	26	1941	2711	1260	212	49	4232
65-69	1671	582	98	35	2386	1523	640	104	20	2287	3194	1222	202	55	4673
70-74	1942	475	71	22	2510	1337	551	106	29	2023	3279	1026	177	51	4533
75-79	1757	290	84	20	2151	1222	376	89	11	1698	2979	666	173	31	3849
80-84	1108	168	43	*	1324	877	241	52	14	1184	1985	409	95	19	2508
85 plus	522	72	16	*	613	504	182	20	*	715	1026	254	36	12	1328
All Age	20772	7694	1208	361	30035	15879	6112	1185	284	23460	36651	13806	2393	645	53495

Missing Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	52	10	*	0	67	42	11	*	0	54	94	21	*	0	121
5- 9	86	21	*	0	113	65	*	*	0	74	151	29	*	0	187
10-14	112	42	0	*	156	90	26	*	0	125	202	68	*	*	281
15-19	201	60	*	*	266	138	74	*	0	220	339	134	11	*	486
20-24	270	120	22	*	414	201	77	12	0	290	471	197	34	*	704
25-29	441	162	12	*	620	377	149	*	*	543	818	311	21	13	1163
30-34	666	263	19	*	957	663	156	25	*	850	1329	419	44	15	1807
35-39	1017	357	29	*	1410	955	210	25	14	1204	1972	567	54	21	2614
40-44	1242	416	51	12	1721	949	254	24	*	1228	2191	670	75	13	2949
45-49	1254	504	53	13	1824	871	271	25	*	1171	2125	775	78	17	2995
50-54	1040	425	41	11	1517	805	245	29	*	1083	1845	670	70	15	2600
55-59	890	382	25	*	1304	607	318	17	*	945	1497	700	42	10	2249
60-64	740	433	31	*	1212	645	409	18	12	1084	1385	842	49	20	2296
65-69	877	417	30	*	1328	742	584	30	19	1375	1619	1001	60	23	2703
70-74	738	293	17	*	1051	608	380	18	*	1015	1346	673	35	12	2066
75-79	611	167	11	*	790	460	233	*	*	701	1071	400	15	*	1491
80-84	277	99	*	0	380	232	138	*	*	380	509	237	11	*	760
85 plus	120	42	*	*	168	122	78	*	0	203	242	120	*	*	371
All Age	10634	4213	363	88	15298	8572	3621	265	87	12545	19206	7834	628	175	27843

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

* Values for cells with fewer than 10 patients are suppressed.

Table B.13
December 31 Point Prevalence Rates per Ten Million Population
of Reported ESRD Therapy by Primary Disease Causing ESRD
Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex
1994-1997

Diabetes

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	*	17	*	*	*	*	*	*	*	13	*	*	*	*	*
5- 9	*	0	0	0	*	*	*	0	*	*	*	0	*	*	*
10-14	*	*	0	0	*	*	0	0	*	*	0	0	*	*	*
15-19	*	20	*	0	*	33	*	0	*	27	*	0	*	11	*
20-24	67	230	*	*	82	343	*	274	74	288	*	191	86	115	101
25-29	507	1010	150	*	566	1369	144	1032	537	1193	147	628	555	655	607
30-34	1627	2260	480	1765	1386	2146	516	2476	1504	2204	499	2131	1666	1460	1561
35-39	2550	3229	1097	3679	1777	2908	1028	3703	2155	3062	1061	3690	2591	1909	2244
40-44	3262	6173	1917	9335	2164	4693	1056	6567	2698	5409	1475	7902	3628	2478	3040
45-49	4113	12617	3500	21489	2690	10177	2403	15786	3380	11330	2939	18537	5306	3730	4500
50-54	4941	21843	7481	35447	3382	20629	4170	29938	4126	21167	5759	32470	7408	5805	6590
55-59	6316	34223	11305	51230	4927	33383	8043	53761	5591	33690	9603	52303	10384	9047	9702
60-64	7653	41114	16041	59819	7063	47470	12322	73628	7354	44318	14088	66830	12645	12944	12809
65-69	8529	39260	20711	61166	8253	55713	18670	86940	8400	47612	19602	74236	13323	15333	14378
70-74	8330	38528	22174	42212	7716	56764	23469	79261	8023	47769	22740	60968	12949	15121	14091
75-79	6608	29028	21393	28554	5520	41638	22682	50641	6020	35326	21842	39649	10121	11073	10631
80-84	4399	19291	18321	16863	3162	24872	17038	30822	3746	22098	17453	23996	6865	6644	6764
85 plus	1843	8086	10623	4571	1045	8078	8599	7974	1424	8031	9404	6186	2953	2257	2598
All Age	2609	7031	2992	9048	2278	9442	2882	11607	2441	8298	2935	10336	3222	3311	3267
Age Adj	2620	10028	4539	13828	2099	11514	3882	16697	2346	10881	4194	15484	3437	3102	3272

Hypertension

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	*	18	0	0	*	27	0	*	*	23	0	*	*	*	*
5- 9	*	*	0	0	*	*	0	*	*	*	0	*	*	*	*
10-14	*	*	0	*	12	17	0	*	10	15	0	*	*	13	11
15-19	27	184	0	*	38	98	72	*	32	141	37	140	47	47	47
20-24	137	1679	264	390	122	692	177	685	129	1175	220	542	339	201	267
25-29	358	4159	600	770	216	1736	239	809	285	2921	414	790	851	414	624
30-34	537	6674	1032	1364	312	3000	582	435	422	4801	804	889	1340	664	989
35-39	703	11314	1500	2285	370	4945	1113	1426	533	8060	1302	1842	2089	985	1515
40-44	979	19274	2261	3836	503	7767	1591	2028	735	13394	1916	2909	3367	1474	2380
45-49	1382	28948	2804	6439	739	11703	2317	2962	1053	20114	2553	4655	4962	2203	3523
50-54	1920	35967	4146	8217	1114	16319	3342	4696	1511	25921	3728	6365	6362	3156	4691
55-59	2775	40546	6370	7037	1606	21942	4245	6101	2177	31034	5265	6537	7721	4316	5950
60-64	4178	43867	7964	10301	2338	29468	5754	7679	3238	36506	6828	8940	9394	5944	7609
65-69	6265	43391	11075	12395	3513	35832	8564	9735	4861	39526	9792	11037	11195	7847	9477
70-74	9252	47655	17093	15202	4691	44841	11140	13190	6924	46209	14015	14175	14455	10085	12226
75-79	12000	46237	23084	14051	5746	42674	15948	17041	8796	44366	19455	15398	16738	10889	13756
80-84	13135	45522	27894	10631	5757	38697	21714	13725	9354	42022	24509	12204	17733	10570	14076
85 plus	9197	28195	18294	8685	3144	23067	10975	8638	6083	25493	14471	8813	11889	5985	8876
All Age	1784	11950	2368	2556	1125	8343	1954	2127	1449	10056	2154	2340	3058	2102	2570
Age Adj	1902	16369	3753	3918	972	10121	2669	3035	1369	13127	3136	3470	3441	1908	2581

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.13(Continued)
December 31 Point Prevalence Rates per Ten Million Population
of Reported ESRD Therapy by Primary Disease Causing ESRD
Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex
1994-1997

Glomeruloneph.

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	21	*	*	0	24	*	*	*	22	14	33	*	20	23	22	
5- 9	77	96	64	217	80	69	115	*	79	82	90	175	80	81	80	
10- 14	174	281	182	*	168	245	318	*	171	263	252	147	187	183	185	
15- 19	359	1152	469	584	364	778	505	1173	361	961	487	895	465	429	446	
20- 24	807	2954	1308	1379	707	2035	1284	1670	756	2485	1295	1528	1103	905	1000	
25- 29	1409	4786	2309	2566	1078	2961	1493	2260	1240	3854	1892	2402	1880	1342	1602	
30- 34	1891	5291	3221	2540	1238	3459	2032	2993	1559	4359	2611	2777	2378	1566	1961	
35- 39	2270	6429	3974	4988	1356	3842	3468	3621	1803	5106	3714	4283	2883	1768	2310	
40- 44	2663	8754	5177	5594	1522	4584	4244	3268	2079	6617	4693	4396	3550	2023	2765	
45- 49	3019	10441	5755	6676	1694	5364	4471	5175	2340	7822	5084	5884	4085	2286	3159	
50- 54	3187	9758	6447	7637	1780	5084	4519	5723	2466	7341	5451	6686	4169	2329	3224	
55- 59	3523	9103	7131	9359	1878	5245	4850	5147	2679	7122	5951	7207	4406	2440	3398	
60- 64	3789	8785	6348	6958	1968	5452	3852	5859	2859	7079	5054	6373	4542	2511	3502	
65- 69	3913	7051	7026	8341	2063	5037	4571	5880	2970	6021	5764	7071	4464	2566	3495	
70- 74	4147	7247	9917	5313	2070	5497	4964	4872	3087	6352	7389	5094	4764	2636	3677	
75- 79	3996	5848	8596	11558	1849	4745	6450	5627	2894	5271	7466	8447	4451	2416	3414	
80- 84	3663	4726	8500	5499	1494	3027	6085	3371	2552	3857	7229	4433	3986	1872	2908	
85 plus	2202	2495	5311	*	692	2221	2211	*	1425	2345	3682	*	2341	939	1627	
All Age	1899	4310	3035	2966	1144	2795	2392	2429	1515	3514	2703	2695	2245	1415	1821	
Age Adj	1908	5043	3628	3862	1100	3038	2594	2881	1476	4012	3070	3334	2338	1378	1825	

Cystic Kidney

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	18	*	0	0	18	*	*	0	18	*	*	0	16	17	16	
5- 9	35	38	*	*	29	16	*	*	32	27	*	*	35	28	32	
10- 14	45	27	*	*	41	40	*	0	43	34	*	*	42	41	41	
15- 19	51	31	*	*	54	58	130	0	52	44	90	*	48	56	53	
20- 24	74	48	*	*	82	40	*	0	78	44	48	*	70	75	73	
25- 29	89	66	90	*	90	33	*	*	89	49	66	*	86	81	83	
30- 34	107	118	*	267	114	123	60	326	110	121	42	298	106	115	111	
35- 39	251	253	146	279	188	237	90	329	219	244	117	304	247	192	219	
40- 44	562	488	358	831	336	590	324	393	447	539	342	609	547	368	456	
45- 49	1126	1162	853	1146	788	974	462	712	953	1064	653	923	1120	799	956	
50- 54	1664	1761	1267	2212	1270	1845	718	1174	1463	1805	987	1683	1666	1322	1491	
55- 59	1877	2022	1552	1267	1643	1730	1025	2288	1755	1870	1278	1791	1875	1635	1752	
60- 64	1741	2046	1444	2078	1698	1929	967	2138	1719	1986	1196	2103	1771	1704	1737	
65- 69	1437	1633	1488	1158	1483	1398	1173	1542	1462	1512	1332	1356	1463	1463	1462	
70- 74	1199	1460	1478	*	1054	1376	915	*	1125	1415	1187	673	1240	1084	1160	
75- 79	706	1214	1449	*	666	1012	886	*	684	1108	1172	1130	798	722	759	
80- 84	526	1027	*	0	342	400	833	0	432	705	683	0	587	363	472	
85 plus	286	631	*	0	86	397	*	*	183	511	*	*	329	126	225	
All Age	538	436	353	440	475	463	277	391	506	450	314	415	518	466	491	
Age Adj	536	592	463	576	446	542	324	502	489	563	389	540	537	452	492	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.13(Continued)
December 31 Point Prevalence Rates per Ten Million Population
of Reported ESRD Therapy by Primary Disease Causing ESRD
Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex
1994-1997

Other Urologic

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	25	53	*	0	*	0	0	0	14	26	*	0	28	*	15	
5- 9	45	62	*	0	11	*	0	0	28	35	*	0	47	*	28	
10- 14	90	100	98	*	38	23	*	*	63	61	55	115	92	35	63	
15- 19	134	204	91	*	80	33	*	*	107	117	59	*	141	72	105	
20- 24	164	178	129	*	131	60	*	*	147	118	87	240	165	120	142	
25- 29	241	228	84	334	140	112	*	*	190	169	61	278	235	133	183	
30- 34	211	231	202	401	153	74	93	354	182	151	146	377	216	143	179	
35- 39	183	243	122	362	173	83	102	329	178	162	112	343	190	160	175	
40- 44	205	252	148	*	155	182	162	*	179	215	153	*	209	158	183	
45- 49	196	311	172	*	185	194	128	*	190	251	151	*	208	183	195	
50- 54	194	379	178	527	196	305	319	*	194	340	253	359	219	213	216	
55- 59	275	535	395	704	238	307	539	*	255	418	465	371	315	255	284	
60- 64	404	789	627	*	270	422	322	*	336	602	465	*	462	290	374	
65- 69	508	1369	683	*	280	523	578	*	392	936	627	710	628	323	471	
70- 74	798	1766	862	1476	276	596	732	*	532	1167	791	959	928	335	624	
75- 79	1059	1673	1497	2266	313	549	567	*	675	1094	1029	1704	1159	358	750	
80- 84	1207	2740	2228	*	196	412	897	0	690	1554	1548	*	1456	247	836	
85 plus	850	1924	1416	*	95	310	*	0	460	1100	928	*	1022	136	569	
All Age	245	317	197	308	149	145	148	158	196	226	172	233	253	149	200	
Age Adj	254	438	283	473	143	168	182	184	191	286	224	303	272	145	200	

Other Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	135	171	69	*	61	67	*	*	98	118	57	*	137	62	99	
5- 9	244	297	70	*	99	140	115	*	170	216	93	156	243	105	173	
10- 14	391	527	286	230	224	211	149	*	306	365	216	177	403	219	309	
15- 19	581	645	497	678	386	565	513	766	481	603	503	728	586	417	500	
20- 24	765	1028	670	1510	659	1422	936	794	712	1230	807	1145	802	768	786	
25- 29	991	1963	720	1155	867	2424	888	1311	928	2198	806	1236	1106	1069	1088	
30- 34	1125	2647	658	1310	1048	3302	1153	1768	1087	2983	909	1546	1303	1344	1325	
35- 39	1087	3247	634	2564	1117	3974	1401	1673	1102	3615	1026	2105	1356	1493	1427	
40- 44	1101	4121	1039	1822	1087	4054	1459	1846	1092	4068	1251	1823	1483	1479	1481	
45- 49	1118	4291	918	2133	1239	3839	1877	2100	1178	4030	1404	2102	1515	1594	1554	
50- 54	1237	4091	934	2370	1336	3812	2414	2299	1284	3940	1689	2328	1592	1695	1644	
55- 59	1407	4209	1450	4293	1512	3689	1656	2224	1458	3933	1555	3234	1786	1795	1789	
60- 64	1753	4530	1635	3886	1650	4055	1964	2533	1701	4285	1802	3195	2118	1974	2044	
65- 69	2170	4093	2293	4286	1869	3710	2259	4530	2018	3896	2276	4416	2437	2141	2286	
70- 74	2561	5114	2310	4280	1804	4014	2905	4278	2176	4551	2612	4260	2890	2147	2510	
75- 79	2831	5117	3284	4759	1648	3261	2693	3858	2221	4160	2978	4301	3146	1905	2511	
80- 84	2894	4977	3136	3666	1281	3074	2434	*	2065	3999	2733	2908	3163	1555	2341	
85 plus	1942	3637	2597	*	566	1936	*	*	1235	2761	1665	2296	2191	747	1453	
All Age	1057	2158	751	1451	948	2298	1131	1304	1002	2232	947	1377	1185	1133	1159	
Age Adj	1073	2594	924	1876	911	2472	1217	1572	980	2515	1066	1707	1239	1103	1159	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.13(Continued)
December 31 Point Prevalence Rates per Ten Million Population
of Reported ESRD Therapy by Primary Disease Causing ESRD
Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex
1994-1997

Unknown Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	15	*	0	0	*	*	0	0	10	10	0	0	14	*	*	
5- 9	31	24	*	0	24	*	*	*	28	15	*	*	30	22	26	
10- 14	57	98	*	*	55	65	*	*	56	81	33	*	60	56	58	
15- 19	101	228	91	234	99	153	144	*	100	189	119	167	118	107	112	
20- 24	230	450	200	468	190	343	288	301	209	395	245	383	258	214	236	
25- 29	369	962	426	488	258	497	222	335	312	724	322	407	447	288	365	
30- 34	416	1053	546	1069	345	628	439	653	380	837	492	855	508	386	445	
35- 39	476	1615	847	975	360	726	384	603	417	1161	609	783	639	409	520	
40- 44	548	1994	702	1407	386	970	744	696	465	1471	723	1041	744	476	606	
45- 49	562	2724	943	1422	417	1294	889	750	488	1992	921	1074	858	547	697	
50- 54	625	2640	1323	1580	463	1498	1187	1321	543	2054	1243	1450	914	629	766	
55- 59	732	2838	1347	1337	556	1996	1143	1779	642	2412	1247	1570	1026	772	895	
60- 64	935	3513	2186	2078	637	2895	1488	2058	783	3197	1830	2061	1318	966	1138	
65- 69	1054	3671	2391	4055	817	3013	1821	1928	933	3336	2104	2970	1462	1142	1298	
70- 74	1416	4153	2187	3247	760	3282	2425	3446	1081	3706	2316	3334	1806	1164	1478	
75- 79	1717	3593	4057	4532	837	2906	3154	1768	1265	3244	3580	3133	2062	1192	1618	
80- 84	1827	3835	3549	*	834	2838	3331	3371	1318	3324	3461	2626	2142	1203	1662	
85 plus	1357	2164	1888	*	515	2258	1638	*	921	2208	1686	1688	1468	785	1121	
All Age	481	1209	643	795	355	868	593	616	417	1030	617	705	579	433	504	
Age Adj	494	1553	854	1113	333	1006	719	808	404	1269	782	955	620	413	506	

Missing Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	17	17	*	0	14	19	*	0	15	18	*	0	17	14	16	
5- 9	27	34	*	0	22	*	*	0	24	23	*	0	28	20	24	
10- 14	36	71	0	*	31	45	*	0	33	58	*	*	39	33	36	
15- 19	66	102	*	*	48	130	*	0	57	116	40	*	68	58	63	
20- 24	92	232	142	*	73	145	79	0	83	188	110	*	112	82	96	
25- 29	142	325	72	*	125	274	*	*	134	298	58	176	163	142	152	
30- 34	190	501	113	*	192	263	137	*	192	382	125	201	228	199	213	
35- 39	271	674	177	*	259	351	141	384	265	507	157	290	318	267	291	
40- 44	357	898	344	384	273	478	144	*	313	676	241	203	423	291	355	
45- 49	414	1401	434	514	284	633	178	*	347	995	299	333	538	322	426	
50- 54	428	1645	456	579	320	771	289	*	369	1189	362	361	578	372	471	
55- 59	466	1856	366	*	300	1207	223	*	380	1519	287	341	636	410	520	
60- 64	446	2531	589	*	354	1797	276	950	399	2155	420	838	717	539	625	
65- 69	553	2630	732	*	398	2749	525	1831	475	2692	626	1171	823	713	767	
70- 74	538	2562	524	*	345	2263	412	*	440	2410	460	760	793	597	693	
75- 79	597	2069	531	*	315	1801	*	*	451	1934	325	*	774	499	634	
80- 84	457	2260	*	0	221	1625	*	*	335	1935	413	*	673	413	540	
85 plus	312	1262	*	*	125	968	*	0	215	1110	*	*	442	235	336	
All Age	246	662	193	194	192	514	133	189	219	584	162	191	295	232	262	
Age Adj	248	874	232	251	184	602	148	261	213	732	188	259	310	223	263	

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.14
Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population
of Reported ESRD Therapy by Primary Disease Causing ESRD
by Sex, Race, and Age, Adjusted for Age, Race, and Sex

1994-1997

Diabetes

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	1.2	5.3	*	*	1.1	*	*	*	0.8	3.3	*	*	1.3	1.1	0.8	
5- 9	*	0.0	0.0	0.0	*	*	*	0.0	*	*	*	0.0	*	0.8	0.5	
10-14	*	*	0.0	0.0	*	*	0.0	0.0	*	*	0.0	0.0	*	*	*	
15-19	1.2	5.9	*	0.0	1.6	7.7	*	0.0	1.0	4.9	*	0.0	1.3	1.7	1.1	
20-24	4.8	21.1	*	*	5.4	25.4	*	86.6	3.6	16.6	*	51.1	4.8	5.6	3.7	
25-29	12.8	45.0	30.0	*	13.7	50.2	28.3	169.7	9.4	33.8	20.6	93.7	12.1	13.1	8.9	
30-34	21.5	65.6	53.4	217.2	20.0	60.2	53.2	259.5	14.7	44.5	37.8	170.2	19.9	18.5	13.6	
35-39	26.1	78.1	81.8	320.2	21.9	69.7	76.2	318.7	17.0	52.1	55.8	225.9	24.1	20.6	15.8	
40-44	30.6	115.4	113.7	546.3	25.0	93.9	79.6	445.8	19.7	74.1	68.9	350.4	29.9	24.3	19.2	
45-49	36.9	187.3	169.4	921.3	29.6	154.2	130.7	769.4	23.5	120.6	106.6	597.2	39.9	32.3	25.5	
50-54	45.1	290.8	288.4	1366.4	36.7	254.8	203.9	1210.2	28.9	192.5	175.0	907.2	54.6	46.1	35.6	
55-59	57.5	407.8	406.9	1898.7	49.3	355.9	325.1	1848.4	37.7	269.2	258.7	1319.7	73.5	63.9	48.5	
60-64	67.9	490.2	552.2	2324.9	62.3	456.7	434.8	2414.3	46.0	334.3	348.9	1677.1	88.5	81.8	60.1	
65-69	73.4	497.6	710.8	2661.9	66.5	512.1	571.8	2894.8	49.5	357.0	452.9	1968.0	94.2	91.2	65.6	
70-74	77.9	580.4	826.4	2496.1	66.2	581.4	732.7	3069.0	51.0	410.3	549.5	1981.8	104.6	99.3	72.1	
75-79	80.4	599.7	1016.4	2543.8	61.5	567.3	896.6	2853.3	50.1	410.8	671.8	1911.4	109.4	96.9	72.9	
80-84	85.2	663.6	1229.6	2486.4	54.9	541.2	1044.7	2724.3	49.9	425.6	796.2	1852.2	120.1	93.6	75.6	
85 plus	69.2	493.0	1119.7	1445.5	32.7	316.6	839.2	1328.9	37.5	288.7	685.5	957.9	94.3	58.1	54.6	
Age Adj	7.8	48.6	63.9	223.4	6.6	44.9	52.9	232.3	5.1	33.0	41.1	163.4	8.4	7.3	5.6	

Hypertension

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	1.0	5.5	0.0	0.0	*	6.8	0.0	*	0.6	4.5	0.0	*	1.1	1.2	0.8	
5- 9	1.4	*	0.0	0.0	1.7	*	0.0	*	1.1	2.7	0.0	*	1.2	1.5	1.0	
10-14	1.6	*	0.0	*	2.1	5.5	0.0	*	1.3	3.6	0.0	*	1.5	1.9	1.2	
15-19	3.0	17.7	0.0	*	3.6	13.1	22.8	*	2.4	11.0	11.7	40.4	3.4	3.6	2.5	
20-24	6.8	56.9	41.3	100.8	6.7	36.1	34.0	136.9	4.8	33.4	26.6	85.7	9.3	7.4	5.9	
25-29	10.7	91.3	60.0	140.6	8.5	56.5	36.4	150.2	6.8	53.2	34.7	103.0	14.8	10.2	8.9	
30-34	12.4	112.8	78.2	190.9	9.5	71.2	56.5	108.8	7.8	66.1	48.1	108.7	17.9	12.2	10.7	
35-39	13.7	146.1	95.6	252.4	10.0	90.9	79.3	197.8	8.4	85.2	61.9	159.2	22.1	14.6	13.0	
40-44	16.8	203.9	123.5	350.2	12.0	120.8	97.7	247.7	10.2	117.4	78.4	212.8	29.8	18.7	17.3	
45-49	21.4	283.6	151.6	504.3	15.5	165.4	128.3	333.3	13.1	162.5	99.1	299.4	40.7	25.2	23.5	
50-54	28.1	373.1	214.7	657.9	21.0	226.7	182.6	479.3	17.5	216.3	140.6	401.5	53.6	34.6	31.3	
55-59	38.1	443.9	305.4	703.7	28.2	288.6	236.2	622.6	23.6	262.5	191.7	467.4	65.7	44.6	39.1	
60-64	50.2	506.4	389.1	964.8	35.8	359.8	297.2	779.7	30.6	308.4	243.6	616.3	78.2	55.9	47.5	
65-69	62.9	523.1	519.8	1198.3	43.4	410.7	387.3	968.7	37.9	330.9	322.4	767.3	87.0	65.4	53.9	
70-74	82.1	645.5	725.5	1497.9	51.6	516.8	504.8	1252.0	48.1	411.6	438.0	973.0	110.4	81.1	67.9	
75-79	108.3	756.9	1055.8	1784.4	62.7	574.3	751.8	1655.2	61.9	472.1	646.1	1203.3	137.7	94.7	82.7	
80-84	147.2	1019.4	1517.2	1974.2	74.0	675.1	1179.3	1818.0	81.3	606.3	949.7	1339.8	186.8	114.7	108.1	
85 plus	154.6	920.6	1469.4	1992.5	56.7	535.0	948.1	1383.2	80.7	525.3	865.9	1243.6	181.8	90.1	99.7	
Age Adj	6.9	61.5	60.7	122.3	4.4	42.1	44.8	99.6	3.8	36.4	36.5	78.1	8.7	5.7	4.9	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is the July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.14(Continued)
 Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population
 of Reported ESRD Therapy by Primary Disease Causing ESRD
 by Sex, Race, and Age, Adjusted for Age, Race, and Sex

1994-1997

Glomeruloneph.

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	2.6	*	*	0.0	2.8	*	*	*	1.9	3.4	9.8	*	2.3	2.5	1.7
5- 9	4.9	12.4	20.2	68.7	5.2	10.7	27.9	*	3.6	8.2	17.3	43.8	4.5	4.6	3.2
10- 14	7.5	21.8	34.5	*	7.6	20.7	46.4	*	5.3	15.0	29.1	39.2	6.9	7.0	4.9
15- 19	10.8	44.3	57.3	116.9	11.3	36.9	60.4	167.6	7.8	28.8	41.7	104.1	10.8	10.8	7.6
20- 24	16.6	75.5	91.8	189.5	16.0	62.0	91.7	213.9	11.5	48.7	64.9	143.3	17.2	15.9	11.7
25- 29	21.3	97.9	117.7	256.6	18.9	73.8	91.0	251.1	14.2	61.0	74.1	179.0	22.1	18.7	14.4
30- 34	23.2	100.4	138.2	260.6	18.9	76.4	105.6	285.3	14.9	62.8	86.4	194.0	23.7	19.0	15.1
35- 39	24.6	110.1	155.6	372.9	19.2	80.1	140.0	315.2	15.5	67.6	104.4	242.9	25.6	19.7	16.0
40- 44	27.7	137.4	186.9	422.9	20.9	92.8	159.6	314.5	17.2	82.3	122.5	261.5	29.8	21.9	18.3
45- 49	31.6	170.3	217.2	513.5	23.5	111.9	178.3	440.5	19.6	100.9	139.8	336.1	35.1	25.2	21.4
50- 54	36.2	194.3	267.7	634.2	26.6	126.5	212.3	529.1	22.3	114.6	170.2	413.7	40.4	28.7	24.5
55- 59	43.0	210.3	323.2	811.5	30.5	141.1	252.5	571.9	26.1	125.5	203.9	493.2	46.5	32.6	28.1
60- 64	47.8	226.6	347.4	792.9	32.9	154.8	243.1	681.0	28.8	136.1	210.0	519.3	51.0	35.2	30.7
65- 69	49.7	210.9	414.0	983.0	33.3	154.0	283.0	752.8	29.7	129.7	248.7	614.8	52.1	35.9	31.4
70- 74	55.0	251.7	552.6	885.6	34.3	180.9	337.0	760.9	32.1	153.9	320.9	583.0	59.7	39.1	35.3
75- 79	62.5	269.2	644.3	1618.4	35.6	191.5	478.1	951.1	35.5	163.7	398.1	921.3	67.6	42.8	39.6
80- 84	77.7	328.5	837.6	1419.8	37.7	188.8	624.3	901.0	42.6	187.4	517.5	839.2	83.4	46.3	47.1
85 plus	75.7	273.8	791.8	*	26.6	166.0	425.6	*	39.3	157.7	440.4	*	77.4	34.4	41.7
Age Adj	6.7	31.4	51.3	111.7	4.9	21.9	38.9	88.5	4.1	18.8	31.4	69.8	6.9	5.0	4.2

Cystic Kidney

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	2.4	*	0.0	0.0	2.4	*	*	0.0	1.7	2.7	*	0.0	2.0	2.1	1.5
5- 9	3.3	7.8	*	*	3.1	5.2	*	*	2.3	4.7	*	*	3.0	2.7	2.0
10- 14	3.8	6.8	*	*	3.7	8.4	*	0.0	2.7	5.4	*	*	3.3	3.3	2.4
15- 19	4.1	7.2	*	*	4.3	10.1	30.6	0.0	3.0	6.2	17.9	*	3.6	4.0	2.7
20- 24	5.0	9.7	*	*	5.5	8.6	*	0.0	3.7	6.5	12.5	*	4.4	4.7	3.2
25- 29	5.4	11.5	23.2	*	5.5	7.8	*	*	3.8	6.9	13.7	*	4.8	4.7	3.3
30- 34	5.5	15.0	*	84.6	5.7	14.4	18.2	94.2	4.0	10.4	11.0	63.5	5.0	5.2	3.6
35- 39	8.2	21.8	29.9	88.1	7.1	19.9	22.6	95.0	5.4	14.7	18.5	64.9	7.4	6.5	4.9
40- 44	12.7	32.4	49.1	163.0	9.8	33.3	44.1	109.1	8.0	23.2	33.1	97.6	11.5	9.4	7.4
45- 49	19.3	56.8	83.6	212.7	16.0	47.7	57.3	163.4	12.5	37.0	50.4	133.3	17.9	14.8	11.6
50- 54	26.2	82.6	118.7	341.3	22.5	76.2	84.6	239.7	17.2	56.2	72.7	207.4	24.7	21.3	16.3
55- 59	31.4	99.1	150.8	298.6	28.5	81.0	116.1	381.3	21.1	63.7	94.4	244.0	29.5	26.3	19.7
60- 64	32.4	109.3	165.7	433.4	30.5	92.0	121.8	411.4	22.2	71.2	101.9	297.9	31.0	28.4	21.0
65- 69	30.1	101.5	190.5	366.3	28.2	81.1	143.4	385.5	20.6	64.6	119.0	266.6	29.1	26.3	19.6
70- 74	29.6	113.0	213.4	*	24.5	90.5	144.7	*	19.1	72.0	127.8	213.7	29.6	24.0	18.9
75- 79	26.3	122.6	264.5	*	21.4	88.5	177.2	*	16.8	75.0	159.8	331.5	28.7	22.3	18.0
80- 84	29.5	153.1	*	0.0	18.0	68.7	230.9	0.0	17.1	82.4	153.8	0.0	32.1	19.1	18.4
85 plus	27.3	137.7	*	0.0	9.4	70.2	*	*	14.2	76.3	*	*	29.4	12.4	15.7
Age Adj	3.5	11.5	18.9	42.5	3.1	9.5	14.2	38.1	2.3	7.4	11.6	28.5	3.3	2.9	2.2

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is the July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.14(Continued)
 Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population
 of Reported ESRD Therapy by Primary Disease Causing ESRD
 by Sex, Race, and Age, Adjusted for Age, Race, and Sex

1994-1997

Other Urologic

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	2.8	9.4	*	0.0	1.2	0.0	0.0	0.0	1.5	4.6	*	0.0	2.6	1.0	1.4
5- 9	3.8	10.0	*	0.0	1.9	*	0.0	0.0	2.1	5.2	*	0.0	3.4	1.6	1.9
10- 14	5.4	13.0	25.2	*	3.6	6.3	*	*	3.2	7.1	13.3	34.6	4.9	3.1	2.9
15- 19	6.6	18.6	25.2	*	5.3	7.7	*	*	4.2	9.9	14.4	*	6.0	4.5	3.7
20- 24	7.5	18.5	28.8	*	6.9	10.7	*	*	5.1	10.6	16.7	56.7	6.7	6.0	4.5
25- 29	8.8	21.4	22.4	92.5	6.8	14.4	*	*	5.5	12.8	13.4	60.9	7.9	6.0	4.9
30- 34	7.8	21.0	34.6	103.6	6.7	11.2	22.6	98.1	5.1	11.8	20.4	71.2	7.2	5.8	4.6
35- 39	7.0	21.4	27.3	100.5	6.8	11.8	24.0	95.0	4.9	12.1	18.2	68.6	6.5	6.0	4.4
40- 44	7.7	23.3	31.7	*	6.7	18.5	31.2	*	5.1	14.7	21.9	*	7.1	6.1	4.7
45- 49	8.0	29.4	37.6	*	7.8	21.3	30.2	*	5.6	18.0	24.2	*	7.7	7.1	5.2
50- 54	8.9	38.3	44.5	166.6	8.8	31.0	56.4	*	6.3	24.4	36.6	96.1	9.1	8.6	6.2
55- 59	12.0	51.0	76.1	222.5	10.8	34.2	84.2	*	8.0	30.4	56.6	112.1	12.3	10.4	8.0
60- 64	15.6	67.9	109.2	*	12.2	43.0	70.3	*	9.9	39.8	63.6	*	16.1	11.8	9.9
65- 69	17.9	92.9	129.1	*	12.3	49.6	100.6	*	10.8	52.0	81.3	197.4	19.8	12.6	11.6
70- 74	24.1	124.3	163.0	466.7	12.5	59.6	129.4	*	13.4	67.9	103.1	257.2	26.4	13.8	14.7
75- 79	32.2	144.0	268.9	716.6	14.6	65.1	141.8	*	17.4	77.6	151.8	419.1	34.3	16.0	18.6
80- 84	44.6	250.1	428.8	*	13.7	69.7	239.7	0.0	22.9	127.8	243.4	*	52.0	16.8	26.7
85 plus	47.0	240.5	408.9	*	9.8	62.0	*	0.0	23.3	122.0	216.1	*	52.5	13.5	26.4
Age Adj	2.5	10.5	16.2	44.6	1.8	5.3	11.0	22.5	1.5	5.4	9.2	22.1	2.4	1.6	1.4

Other Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	6.6	16.9	19.9	*	4.5	10.7	*	*	4.0	10.0	12.8	*	5.9	4.1	3.6
5- 9	8.8	21.8	21.2	*	5.8	15.2	27.9	*	5.2	13.2	17.6	41.7	7.8	5.3	4.7
10- 14	11.3	29.9	43.2	69.2	8.8	19.2	31.7	*	7.1	17.6	26.7	43.0	10.2	7.7	6.4
15- 19	13.8	33.1	59.0	125.9	11.6	31.5	60.8	135.5	9.0	22.8	42.3	93.3	12.4	10.7	8.2
20- 24	16.2	44.6	65.7	198.2	15.5	51.8	78.3	147.5	11.2	34.3	51.4	122.9	14.8	14.8	10.5
25- 29	17.9	62.7	65.7	172.1	17.0	66.8	70.2	191.2	12.3	45.9	48.2	129.1	17.0	16.7	11.9
30- 34	17.9	71.0	62.5	187.2	17.4	74.7	79.6	219.3	12.5	51.6	50.7	144.9	17.6	17.6	12.5
35- 39	17.0	78.3	62.2	267.3	17.4	81.5	88.9	214.2	12.2	56.5	54.7	170.2	17.5	18.1	12.6
40- 44	17.8	94.3	83.8	241.4	17.7	87.3	93.6	236.4	12.5	63.9	62.9	167.9	19.3	18.8	13.4
45- 49	19.2	109.2	86.8	290.3	20.1	94.7	115.5	280.6	13.9	71.7	72.6	200.6	21.4	21.0	15.0
50- 54	22.6	125.8	101.9	353.3	23.0	109.5	155.2	335.4	16.1	83.1	93.9	243.1	25.0	24.4	17.5
55- 59	27.2	143.0	145.7	549.6	27.3	118.3	147.5	376.0	19.2	92.3	103.9	330.4	29.7	27.8	20.3
60- 64	32.5	162.7	176.3	592.5	30.1	133.5	173.6	447.8	22.1	104.8	123.8	369.3	34.9	31.0	23.3
65- 69	37.0	160.7	236.5	704.7	31.7	132.2	198.9	660.8	24.3	103.6	154.1	483.2	38.3	32.5	25.0
70- 74	43.2	211.4	266.7	794.8	32.0	154.6	257.8	713.0	26.7	130.1	185.4	530.3	46.3	34.9	28.8
75- 79	52.6	251.8	398.2	1038.5	33.6	158.8	309.0	787.6	30.9	147.2	251.3	650.2	56.6	36.7	33.3
80- 84	69.1	337.1	508.7	1159.3	34.9	190.3	394.8	*	38.1	191.2	315.9	677.5	74.2	40.8	41.7
85 plus	71.0	330.6	553.6	*	24.0	155.0	*	*	36.8	179.8	302.3	697.7	75.8	29.6	39.9
Age Adj	5.0	23.1	26.8	79.1	4.5	19.6	26.5	66.4	3.3	14.9	18.6	50.5	5.0	4.5	3.3

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is the July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.14(Continued)
 Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population
 of Reported ESRD Therapy by Primary Disease Causing ESRD
 by Sex, Race, and Age, Adjusted for Age, Race, and Sex

1994-1997

Unknown Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	2.2	*	0.0	0.0	1.3	*	0.0	0.0	1.3	2.9	0.0	0.0	1.9	1.2	1.1
5- 9	3.2	6.2	*	0.0	2.8	*	*	*	2.1	3.5	*	*	2.8	2.4	1.8
10- 14	4.3	12.9	*	*	4.3	10.6	*	*	3.0	8.3	10.6	*	3.9	3.9	2.8
15- 19	5.7	19.7	25.2	73.9	5.9	16.4	32.3	*	4.1	12.7	20.8	44.6	5.5	5.4	3.9
20- 24	8.9	29.5	35.9	110.4	8.3	25.4	43.4	90.8	6.1	19.4	28.4	71.1	8.4	7.8	5.7
25- 29	10.9	43.9	50.5	111.9	9.3	30.2	35.1	96.6	7.1	26.4	30.6	73.2	10.8	8.7	6.9
30- 34	10.9	44.8	56.9	169.1	10.0	32.6	49.1	133.3	7.4	27.5	37.6	106.9	11.0	9.5	7.2
35- 39	11.3	55.2	71.9	164.9	9.9	34.8	46.6	128.7	7.5	32.4	42.4	103.8	12.0	9.5	7.6
40- 44	12.5	65.6	68.8	212.1	10.5	42.7	66.8	145.1	8.2	38.8	48.0	127.3	13.7	10.6	8.6
45- 49	13.6	87.0	87.9	237.0	11.7	55.0	79.5	167.7	8.9	51.1	59.6	143.6	16.3	12.3	10.1
50- 54	16.0	101.1	121.3	288.5	13.6	68.7	108.8	254.2	10.5	60.6	80.9	192.4	19.2	15.0	12.0
55- 59	19.6	117.4	140.5	306.7	16.6	87.0	122.6	336.3	12.8	72.8	93.4	229.2	22.8	18.4	14.6
60- 64	23.7	143.3	203.8	433.4	18.7	112.8	151.1	403.7	15.0	90.7	126.3	294.9	28.0	22.1	17.7
65- 69	25.8	152.2	241.5	685.3	20.9	119.1	178.6	431.1	16.5	96.2	149.8	401.4	30.7	24.2	19.4
70- 74	32.1	190.5	259.5	692.3	20.8	139.8	235.5	639.9	19.0	117.4	175.7	468.6	37.6	26.8	22.9
75- 79	41.0	211.0	442.6	1013.5	23.9	149.9	334.3	533.2	23.4	128.6	275.4	569.5	47.0	30.5	27.7
80- 84	54.9	295.9	541.2	*	28.2	182.8	461.9	901.0	30.4	172.2	357.8	614.7	62.6	38.0	36.1
85 plus	59.4	255.1	472.1	*	22.9	167.4	366.3	*	31.2	151.1	285.4	524.3	61.3	31.8	34.1
Age Adj	3.4	18.5	26.5	63.1	2.7	13.0	21.9	49.4	2.1	11.0	17.0	39.5	3.6	2.7	2.2

Missing Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	2.3	5.3	*	0.0	2.2	5.7	*	0.0	1.6	3.9	*	0.0	2.1	1.9	1.4
5- 9	2.9	7.3	*	0.0	2.7	*	*	0.0	2.0	4.3	*	0.0	2.7	2.3	1.8
10- 14	3.4	11.0	0.0	*	3.2	8.9	*	0.0	2.4	7.0	*	*	3.2	3.0	2.2
15- 19	4.6	13.2	*	*	4.1	15.1	*	0.0	3.1	10.0	12.0	*	4.2	4.0	2.9
20- 24	5.6	21.2	30.2	*	5.2	16.6	22.7	0.0	3.8	13.4	18.9	*	5.5	4.8	3.7
25- 29	6.8	25.5	20.8	*	6.4	22.5	*	*	4.7	16.9	12.8	49.0	6.5	6.1	4.5
30- 34	7.3	30.9	25.9	*	7.5	21.1	27.5	*	5.3	18.7	18.9	52.0	7.4	6.9	5.0
35- 39	8.5	35.7	32.8	*	8.4	24.2	28.2	102.6	6.0	21.3	21.3	63.3	8.5	7.7	5.7
40- 44	10.1	44.0	48.2	110.7	8.9	30.0	29.4	*	6.7	26.2	27.9	56.2	10.2	8.3	6.5
45- 49	11.7	62.4	59.7	142.4	9.6	38.5	35.5	*	7.5	35.9	34.0	80.7	12.7	9.4	7.8
50- 54	13.3	79.8	71.2	174.7	11.3	49.3	53.7	*	8.6	46.1	43.5	93.3	15.1	11.4	9.4
55- 59	15.6	95.0	73.2	*	12.2	67.7	54.2	*	9.8	57.7	44.4	107.9	17.9	13.4	11.1
60- 64	16.4	121.6	105.8	*	14.0	88.8	65.1	274.3	10.7	74.8	60.2	187.5	21.0	16.5	13.2
65- 69	18.7	128.8	133.6	*	14.6	113.8	95.9	420.1	11.8	85.8	81.8	244.5	23.1	19.5	15.1
70- 74	19.8	149.6	127.0	*	14.0	116.1	97.0	*	12.1	94.3	78.5	220.2	25.6	19.3	15.9
75- 79	24.1	160.1	160.2	*	14.7	118.0	*	*	13.9	99.0	84.1	*	29.0	19.7	17.3
80- 84	27.4	227.1	*	0.0	14.5	138.3	*	*	15.3	131.6	124.8	*	37.0	22.6	21.3
85 plus	28.5	194.8	*	*	11.3	109.6	*	0.0	15.0	110.5	*	*	35.6	17.6	19.5
Age Adj	2.4	14.0	13.0	28.3	2.0	10.1	9.5	28.8	1.5	8.4	7.9	20.4	2.5	2.0	1.6

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31, 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996,

U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.15
December 31 Point Prevalence Counts
of Reported ESRD Therapy
by State after Dropping Territories and Unknown States

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	1,879	3,211	3,472	3,795	4,176	4,502	4,911	5,347	5,891	6,308
Alaska	131	151	166	196	230	248	408	636	526	378
Arizona	1,895	2,177	2,433	2,719	3,066	3,334	3,653	4,043	4,316	4,618
Arkansas	1,236	1,320	1,459	1,633	1,765	1,947	2,219	2,488	2,653	2,837
California	15,185	16,951	18,814	20,834	22,508	23,975	26,449	28,701	30,653	32,077
Colorado	1,271	1,463	1,627	1,795	2,016	2,191	2,410	2,536	2,720	2,914
Connecticut	1,783	1,956	2,144	2,365	2,568	2,722	2,924	3,177	3,429	3,590
Delaware	438	464	522	584	673	721	773	845	914	964
District of Columbia	817	921	1,006	1,110	1,216	1,340	1,374	1,457	1,565	1,593
Florida	7,393	8,237	9,230	10,247	11,366	12,295	13,147	14,344	15,756	16,725
Georgia	4,195	4,731	5,261	5,926	6,630	7,256	8,091	8,920	9,645	10,208
Hawaii	741	825	889	978	1,055	1,185	1,332	1,428	1,492	1,588
Idaho	362	412	481	520	549	609	672	712	780	878
Illinois	6,850	7,398	8,190	9,071	9,843	10,717	11,741	12,761	13,512	14,123
Indiana	2,918	3,208	3,532	3,836	4,267	4,661	4,908	5,384	5,830	6,144
Iowa	1,329	1,473	1,627	1,756	1,955	2,087	2,243	2,334	2,484	2,587
Kansas	1,102	1,242	1,418	1,554	1,680	1,768	1,941	2,061	2,175	2,383
Kentucky	1,782	1,942	2,138	2,397	2,681	2,907	2,976	3,326	3,546	3,762
Louisiana	2,962	3,284	3,618	3,985	4,388	4,756	5,188	5,706	6,092	6,573
Maine	487	525	582	614	674	734	816	912	963	1,017
Maryland	2,832	3,174	3,622	4,086	4,512	4,918	5,286	5,872	6,567	6,992
Massachusetts	3,049	3,294	3,571	3,879	4,274	4,631	4,997	5,378	5,691	5,947
Michigan	4,927	5,575	6,197	6,777	7,563	8,279	9,104	9,925	10,819	11,378
Minnesota	2,111	2,312	2,580	2,806	3,052	3,278	3,559	3,845	4,119	4,405
Mississippi	1,840	2,037	2,240	2,467	2,733	3,015	3,373	3,655	3,974	4,241
Missouri	2,815	3,175	3,519	3,862	4,187	4,578	4,945	5,409	5,797	6,084
Montana	325	385	428	469	506	545	587	664	685	739
Nebraska	693	786	866	940	1,080	1,148	1,265	1,400	1,453	1,577
Nevada	520	580	633	730	814	889	997	1,118	1,239	1,352
New Hampshire	414	484	526	572	602	635	689	743	752	787
New Jersey	4,778	5,204	5,771	6,406	6,985	7,428	8,149	8,786	9,351	9,778
New Mexico	808	898	1,009	1,145	1,264	1,352	1,479	1,672	1,818	1,973
New York	10,715	11,626	12,614	13,825	15,116	16,294	17,745	19,046	20,188	21,206
North Carolina	4,054	4,520	5,100	5,652	6,348	7,046	7,813	8,491	9,215	9,913
North Dakota	266	335	375	412	461	501	548	556	565	586
Ohio	5,926	6,597	7,273	7,928	8,689	9,358	10,025	11,068	11,968	12,540
Oklahoma	1,404	1,593	1,789	1,942	2,156	2,387	2,635	2,919	3,100	3,333
Oregon	1,259	1,419	1,570	1,758	1,860	2,002	2,180	2,326	2,484	2,594
Pennsylvania	7,291	7,992	8,870	9,634	10,425	11,047	12,071	13,225	14,001	14,628
Rhode Island	526	599	645	707	753	808	880	935	1,001	1,021
South Carolina	2,496	2,799	3,132	3,426	3,766	4,091	4,545	5,009	5,418	5,756
South Dakota	356	377	406	437	458	511	564	644	712	754
Tennessee	2,756	3,187	3,482	3,872	4,271	4,549	5,094	5,591	6,010	6,369
Texas	9,457	10,602	11,920	13,314	14,865	16,295	18,020	19,524	21,241	22,621
Utah	684	745	784	868	927	1,057	1,155	1,259	1,305	1,375
Vermont	224	239	254	291	306	321	349	403	430	482
Virginia	3,703	4,064	4,447	4,979	5,538	6,042	6,394	7,004	7,728	8,386
Washington	2,101	2,354	2,587	2,832	3,006	3,270	3,600	3,901	4,183	4,393
West Virginia	926	1,012	1,080	1,196	1,284	1,390	1,488	1,618	1,736	1,908
Wisconsin	2,517	2,825	3,056	3,388	3,771	4,040	4,412	4,753	5,092	5,382
Wyoming	166	184	190	208	209	229	253	283	303	325
	136,695	152,864	169,145	186,723	205,087	221,889	242,377	264,140	283,887	300,092

Includes residents of 50 states and District of Columbia only.
Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Table B.16
 December 31 Point Prevalence Rates per Million Population
 of Reported ESRD Therapy
 by State Adjusted for Age, Race, and Sex

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	502.91	846.03	898.42	963.66	1040.86	1103.20	1187.38	1276.71	1383.82	1455.08
Alaska	267.69	314.11	328.30	376.26	420.64	441.68	713.91	1100.24	884.37	618.17
Arizona	556.27	623.95	678.97	737.61	800.98	833.09	873.60	933.33	965.35	1000.59
Arkansas	542.66	576.24	630.62	698.12	741.88	807.00	906.93	1003.66	1057.74	1120.86
California	550.57	600.29	654.66	710.89	754.28	792.68	862.78	922.55	965.65	987.79
Colorado	422.04	477.95	514.95	553.49	597.19	625.73	666.79	681.64	710.44	741.31
Connecticut	588.56	639.36	691.98	757.56	816.66	860.55	919.08	990.65	1058.74	1097.48
Delaware	741.77	769.75	844.31	927.03	1048.61	1088.46	1142.66	1212.49	1278.08	1310.43
District of Columbia	1386.39	1577.59	1754.37	1946.68	2153.13	2400.29	2506.78	2700.86	2945.19	3041.20
Florida	634.92	687.96	750.59	812.59	878.21	925.64	962.97	1024.16	1095.50	1132.25
Georgia	717.05	790.99	856.07	937.93	1016.90	1080.10	1169.53	1254.79	1316.78	1349.87
Hawaii	773.99	833.42	871.81	912.05	962.83	1060.44	1174.38	1242.04	1276.51	1336.22
Idaho	377.98	421.33	477.82	496.91	507.86	548.60	588.09	608.39	651.62	718.76
Illinois	627.23	669.86	734.38	803.65	862.11	928.77	1008.87	1088.99	1143.74	1184.70
Indiana	556.31	605.57	656.34	700.87	768.40	830.67	864.19	936.55	1003.17	1044.52
Iowa	506.74	554.98	605.58	643.48	710.25	750.17	798.73	824.79	873.47	906.25
Kansas	472.61	525.11	591.95	639.09	681.42	709.46	768.02	807.50	844.48	915.59
Kentucky	512.39	554.41	603.49	665.72	733.91	784.59	790.44	872.29	917.18	959.41
Louisiana	772.27	851.20	929.90	1006.02	1088.15	1163.11	1252.41	1355.83	1422.30	1508.52
Maine	421.18	452.59	495.15	517.87	567.01	610.95	675.08	748.97	783.28	817.66
Maryland	674.62	738.83	825.96	912.91	987.70	1051.99	1106.50	1202.14	1314.56	1367.95
Massachusetts	543.90	582.04	628.28	677.78	742.34	794.85	847.66	901.87	942.15	969.58
Michigan	566.94	636.11	696.05	749.82	825.22	890.78	967.61	1039.36	1118.04	1161.57
Minnesota	522.31	563.50	618.45	661.05	705.13	743.59	793.56	843.39	889.10	936.43
Mississippi	769.77	843.89	919.81	992.32	1084.46	1174.54	1293.19	1380.17	1476.32	1547.60
Missouri	574.58	642.41	704.86	763.30	818.25	883.52	943.39	1020.07	1081.48	1122.25
Montana	424.61	493.83	546.92	584.75	620.92	657.53	690.70	767.42	784.12	839.89
Nebraska	466.45	523.83	568.88	607.45	687.93	725.11	786.72	859.93	883.30	949.45
Nevada	521.00	548.75	561.78	597.83	633.38	656.55	691.13	731.00	764.28	788.43
New Hampshire	403.52	466.60	500.57	536.87	558.99	581.16	618.66	652.12	648.31	667.54
New Jersey	658.83	711.45	782.34	856.71	924.90	971.26	1052.11	1120.39	1175.49	1210.40
New Mexico	592.41	644.50	706.52	772.38	826.18	859.27	915.67	1008.73	1069.43	1134.56
New York	634.23	682.20	733.50	798.42	866.07	926.57	1001.75	1068.13	1123.14	1169.10
North Carolina	653.52	715.55	790.91	859.79	947.93	1029.65	1115.98	1186.94	1260.01	1324.69
North Dakota	437.28	563.11	624.58	687.86	748.50	812.92	880.45	880.66	888.48	915.61
Ohio	579.30	639.77	696.97	749.97	811.55	864.67	917.25	1005.04	1077.71	1119.83
Oklahoma	472.18	532.70	591.21	634.50	691.27	755.01	823.67	900.02	943.85	1001.51
Oregon	471.59	517.64	560.29	610.36	632.58	663.98	708.95	741.37	776.06	793.98
Pennsylvania	641.18	697.24	766.94	826.91	888.18	936.47	1018.94	1110.63	1170.43	1218.04
Rhode Island	552.92	625.12	667.52	734.41	786.17	839.17	911.24	964.92	1022.06	1034.45
South Carolina	789.10	867.92	950.19	1018.01	1098.61	1170.75	1276.60	1384.59	1468.98	1521.97
South Dakota	536.87	563.96	599.72	633.71	659.50	724.47	794.73	895.01	973.95	1021.43
Tennessee	602.97	689.06	737.93	805.57	873.18	911.19	1000.80	1076.62	1134.84	1179.75
Texas	608.06	667.40	733.79	796.06	863.35	921.27	991.76	1047.30	1111.40	1153.34
Utah	424.91	454.68	463.75	496.09	514.11	565.80	599.27	635.29	642.94	661.08
Vermont	439.10	471.12	481.37	541.63	559.16	572.53	615.89	704.31	738.97	816.62
Virginia	661.50	711.64	763.26	834.14	904.86	965.01	1001.61	1076.13	1165.60	1239.08
Washington	470.83	512.96	549.14	581.58	600.32	637.16	682.62	722.15	757.20	776.73
West Virginia	534.94	588.14	623.70	682.19	723.70	780.88	830.75	901.22	963.08	1052.12
Wisconsin	556.14	614.64	654.65	713.55	781.04	823.53	885.19	940.06	994.03	1038.71
Wyoming	382.16	431.75	436.97	470.74	463.96	499.72	544.18	597.14	636.97	677.64

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Rates per million based on the December 31, 1996 U.S. resident population by state for 5-year age groups, sex, and
 White/non-White race groups.

Table B.17
Standard Errors for Adjusted December 31 Point Prevalence Rates
per Million Population of Reported ESRD Therapy
by State Adjusted for Age, Race, and Sex

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	11.80	15.13	15.42	15.77	16.19	16.48	16.95	17.44	17.99	18.27
Alaska	24.59	26.84	26.60	27.75	28.34	28.45	35.62	43.64	38.51	31.76
Arizona	12.96	13.53	13.91	14.25	14.53	14.46	14.47	14.67	14.67	14.70
Arkansas	15.69	16.08	16.70	17.43	17.76	18.35	19.27	20.11	20.50	21.00
California	4.56	4.69	4.83	4.97	5.06	5.14	5.31	5.45	5.51	5.51
Colorado	12.14	12.77	13.01	13.24	13.43	13.46	13.63	13.56	13.62	13.72
Connecticut	14.28	14.73	15.16	15.72	16.22	16.56	17.02	17.58	18.06	18.28
Delaware	36.12	36.26	37.41	38.67	40.63	40.63	41.11	41.67	42.17	42.09
District of Columbia	49.35	52.69	55.92	58.89	62.07	65.75	67.65	70.64	74.20	75.89
Florida	7.51	7.69	7.91	8.10	8.28	8.37	8.41	8.55	8.72	8.74
Georgia	11.30	11.69	11.96	12.29	12.56	12.71	13.01	13.27	13.37	13.32
Hawaii	29.92	30.49	30.57	29.83	30.06	31.04	32.29	32.91	33.02	33.48
Idaho	20.36	21.22	22.13	21.99	21.82	22.32	22.73	22.82	23.32	24.23
Illinois	7.69	7.87	8.19	8.49	8.72	8.99	9.32	9.63	9.83	9.95
Indiana	10.43	10.80	11.14	11.39	11.81	12.19	12.34	12.76	13.12	13.30
Iowa	14.16	14.67	15.19	15.48	16.15	16.47	16.89	17.08	17.51	17.79
Kansas	14.50	15.11	15.90	16.36	16.73	16.94	17.46	17.79	18.09	18.73
Kentucky	12.31	12.73	13.18	13.70	14.24	14.59	14.51	15.13	15.39	15.62
Louisiana	14.41	15.04	15.62	16.05	16.50	16.90	17.40	17.93	18.18	18.56
Maine	19.49	20.09	20.83	21.14	21.99	22.64	23.69	24.82	25.23	25.62
Maryland	12.90	13.32	13.88	14.40	14.78	15.04	15.23	15.68	16.19	16.32
Massachusetts	10.08	10.33	10.66	11.00	11.44	11.73	12.02	12.30	12.48	12.56
Michigan	8.21	8.64	8.94	9.18	9.54	9.82	10.15	10.43	10.73	10.87
Minnesota	11.64	11.95	12.37	12.63	12.86	13.05	13.33	13.61	13.84	14.09
Mississippi	18.30	19.01	19.71	20.17	20.87	21.46	22.28	22.81	23.36	23.70
Missouri	10.96	11.51	11.97	12.35	12.69	13.08	13.42	13.86	14.18	14.36
Montana	24.12	25.71	27.05	27.46	27.91	28.35	28.60	29.80	29.94	30.85
Nebraska	18.07	19.02	19.61	20.02	21.09	21.50	22.17	22.99	23.15	23.87
Nevada	23.48	23.38	22.86	22.44	22.41	22.17	21.96	21.89	21.70	21.42
New Hampshire	20.20	21.53	22.09	22.64	22.92	23.15	23.63	23.94	23.63	23.78
New Jersey	9.75	10.05	10.46	10.82	11.14	11.31	11.67	11.95	12.14	12.22
New Mexico	21.19	21.80	22.49	22.99	23.34	23.42	23.82	24.65	25.03	25.47
New York	6.23	6.41	6.60	6.84	7.08	7.28	7.53	7.74	7.90	8.01
North Carolina	10.40	10.76	11.17	11.51	11.95	12.29	12.63	12.86	13.09	13.27
North Dakota	27.41	31.32	32.81	34.88	35.11	36.48	37.78	37.44	37.36	37.76
Ohio	7.63	7.97	8.25	8.48	8.74	8.96	9.17	9.55	9.84	9.98
Oklahoma	12.77	13.49	14.11	14.50	14.95	15.49	16.07	16.66	16.94	17.32
Oregon	13.61	14.01	14.38	14.73	14.79	14.92	15.23	15.39	15.57	15.58
Pennsylvania	7.65	7.92	8.24	8.50	8.75	8.94	9.28	9.65	9.88	10.05
Rhode Island	24.73	26.11	26.77	27.98	28.92	29.68	30.79	31.57	32.27	32.32
South Carolina	16.05	16.63	17.17	17.53	17.99	18.34	18.94	19.54	19.90	19.99
South Dakota	29.05	29.54	30.29	30.73	31.11	32.22	33.54	35.26	36.43	37.09
Tennessee	11.69	12.38	12.65	13.05	13.43	13.55	14.03	14.39	14.61	14.75
Texas	6.39	6.59	6.82	6.97	7.12	7.24	7.40	7.50	7.62	7.65
Utah	16.53	16.92	16.77	16.99	16.99	17.47	17.66	17.92	17.79	17.81
Vermont	30.04	31.20	30.74	32.14	32.23	32.14	33.06	35.13	35.63	37.15
Virginia	11.07	11.32	11.58	11.91	12.22	12.44	12.53	12.85	13.23	13.50
Washington	10.51	10.78	10.97	11.06	11.04	11.20	11.41	11.57	11.70	11.71
West Virginia	17.89	18.78	19.25	19.93	20.33	21.03	21.58	22.42	23.10	24.06
Wisconsin	11.28	11.73	11.98	12.37	12.79	13.00	13.34	13.64	13.92	14.14
Wyoming	30.49	32.58	32.40	33.08	32.42	33.30	34.41	35.59	36.58	37.54

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Rates per million based on the December 31, 1996 U.S. resident population by state for 5-year age groups, sex, and

White/non-White race groups.

Table B.18
December 31 Point Prevalence Counts
of Reported ESRD Therapy
by Network before Dropping Territories and Unknown Networks

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	6,483	7,097	7,722	8,428	9,177	9,851	10,655	11,548	12,266	12,844
(NY) Net. of N.Y.	10,715	11,626	12,614	13,825	15,116	16,294	17,745	19,046	20,188	21,206
(NJ) Trans-Atlantic R. C.	6,437	7,075	7,852	8,658	9,486	10,091	11,082	11,902	12,698	13,337
(PA) ESRD Net. Org. #4	7,729	8,456	9,392	10,218	11,098	11,768	12,844	14,070	14,915	15,592
(VA) Mid Atlantic R. C.	8,278	9,171	10,155	11,371	12,550	13,690	14,542	15,951	17,596	18,879
(NC) Southeastern Kidney Council	10,745	12,050	13,493	15,004	16,744	18,393	20,449	22,420	24,278	25,877
(FL) ESRD Net. of Florida	7,393	8,237	9,230	10,247	11,366	12,295	13,147	14,344	15,756	16,725
(MS) Network 8	6,475	8,435	9,194	10,134	11,180	12,066	13,378	14,593	15,875	16,918
(IN) Tri-state R. N.	10,626	11,747	12,943	14,161	15,637	16,926	17,909	19,778	21,344	22,446
(IL) Renal Net. of Illinois	6,850	7,398	8,190	9,071	9,843	10,717	11,741	12,761	13,512	14,123
(MN) Renal Net. of upper midwest	10,177	11,424	12,614	13,820	15,305	16,609	18,187	19,723	21,307	22,505
(MD) ESRD net. #12	5,939	6,676	7,430	8,112	8,902	9,581	10,394	11,204	11,909	12,631
(OK) ESRD net. #13	5,602	6,197	6,866	7,560	8,309	9,090	10,042	11,113	11,845	12,743
(TX) Net. of Texas	9,457	10,602	11,920	13,314	14,865	16,295	18,020	19,524	21,241	22,621
(CO) Inter-mountain ESRD net.	5,344	6,047	6,676	7,465	8,296	9,052	9,947	10,911	11,701	12,557
(WA) Northwest Renal Net.	4,178	4,721	5,232	5,775	6,151	6,674	7,447	8,239	8,658	8,982
(N-CA) Trans-pacific ESRD Net.	6,629	7,421	8,259	9,148	9,911	10,783	11,872	12,611	13,343	14,156
(S-CA) Southern California Net.	9,356	10,430	11,536	12,773	13,787	14,525	16,073	17,719	19,045	19,786
Unknown Network	242	726	939	1,175	1,434	1,812	3,000	3,386	2,995	4,039
	138,655	155,536	172,257	190,259	209,157	226,512	248,474	270,843	290,472	307,967

Table B.19
December 31 Point Prevalence Counts
of Reported ESRD Therapy
by Network after Dropping Territories and Unknown Networks

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	6,483	7,097	7,722	8,428	9,177	9,851	10,655	11,548	12,266	12,844
(NY) Net. of N.Y.	10,715	11,626	12,614	13,825	15,116	16,294	17,745	19,046	20,188	21,206
(NJ) Trans-Atlantic R. C.	4,778	5,204	5,771	6,406	6,985	7,428	8,149	8,786	9,351	9,778
(PA) ESRD Net. Org. #4	7,729	8,456	9,392	10,218	11,098	11,768	12,844	14,070	14,915	15,592
(VA) Mid Atlantic R. C.	8,278	9,171	10,155	11,371	12,550	13,690	14,542	15,951	17,596	18,879
(NC) Southeastern Kidney Council	10,745	12,050	13,493	15,004	16,744	18,393	20,449	22,420	24,278	25,877
(FL) ESRD Net. of Florida	7,393	8,237	9,230	10,247	11,366	12,295	13,147	14,344	15,756	16,725
(MS) Network 8	6,475	8,435	9,194	10,134	11,180	12,066	13,378	14,593	15,875	16,918
(IN) Tri-state R. N.	10,626	11,747	12,943	14,161	15,637	16,926	17,909	19,778	21,344	22,446
(IL) Renal Net. of Illinois	6,850	7,398	8,190	9,071	9,843	10,717	11,741	12,761	13,512	14,123
(MN) Renal Net. of upper midwest	10,177	11,424	12,614	13,820	15,305	16,609	18,187	19,723	21,307	22,505
(MD) ESRD net. #12	5,939	6,676	7,430	8,112	8,902	9,581	10,394	11,204	11,909	12,631
(OK) ESRD net. #13	5,602	6,197	6,866	7,560	8,309	9,090	10,042	11,113	11,845	12,743
(TX) Net. of Texas	9,457	10,602	11,920	13,314	14,865	16,295	18,020	19,524	21,241	22,621
(CO) Inter-mountain ESRD net.	5,344	6,047	6,676	7,465	8,296	9,052	9,947	10,911	11,701	12,557
(WA) Northwest Renal Net.	4,178	4,721	5,232	5,775	6,151	6,674	7,447	8,239	8,658	8,982
(N-CA) Trans-pacific ESRD Net.	6,570	7,346	8,167	9,039	9,776	10,635	11,708	12,410	13,100	13,879
(S-CA) Southern California Net.	9,356	10,430	11,536	12,773	13,787	14,525	16,073	17,719	19,045	19,786
	136,695	152,864	169,145	186,723	205,087	221,889	242,377	264,140	283,887	300,092

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories for Table B. 18.
Includes residents of 50 states and District of Columbia only for Table B. 19.
Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Table B.20
December 31 Point Prevalence Rates per Million Population
of Reported ESRD Therapy
by Network Adjusted for Age, Race, and Sex

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	527.73	572.43	617.43	668.86	723.97	769.26	823.90	883.67	927.17	958.17
(NY) Net. of N.Y.	634.23	682.20	733.50	798.42	866.07	926.57	1001.75	1068.13	1123.14	1169.10
(NJ) Trans-Atlantic R. C.	658.83	711.45	782.34	856.71	924.90	971.26	1052.11	1120.39	1175.49	1210.40
(PA) ESRD Net. Org. #4	646.32	701.30	771.45	832.65	897.21	945.32	1026.11	1116.62	1176.68	1223.37
(VA) Mid Atlantic R. C.	678.11	739.57	805.86	885.95	960.09	1028.24	1074.82	1160.44	1259.50	1327.97
(NC) Southeastern Kidney Council	705.69	776.34	849.20	922.93	1005.80	1078.61	1170.12	1253.87	1324.62	1374.43
(FL) ESRD Net. of Florida	634.92	687.96	750.59	812.59	878.21	925.64	962.97	1024.16	1095.50	1132.25
(MS) Network 8	604.10	777.52	833.57	901.31	977.71	1035.90	1129.95	1212.97	1296.37	1356.25
(IN) Tri-state R. N.	560.02	613.84	667.98	720.12	784.82	840.11	878.81	961.07	1026.84	1068.79
(IL) Renal Net. of Illinois	627.23	669.86	734.38	803.65	862.11	928.77	1008.87	1088.99	1143.74	1184.70
(MN) Renal Net. of upper midwest	549.95	610.32	663.47	715.31	779.90	833.81	899.78	961.16	1024.25	1068.66
(MD) ESRD net. #12	523.45	582.20	640.30	689.47	748.15	796.01	853.35	910.19	958.82	1007.30
(OK) ESRD net. #13	617.09	678.94	745.53	808.26	872.64	941.60	1027.07	1120.20	1176.12	1247.32
(TX) Net. of Texas	608.06	667.40	733.79	796.06	863.35	921.27	991.76	1047.30	1111.40	1153.34
(CO) Inter-mountain ESRD net.	497.60	550.17	588.31	635.59	680.10	713.07	753.57	798.64	829.38	862.46
(WA) Northwest Renal Net.	448.19	493.74	533.82	570.55	592.20	626.98	683.06	739.30	760.03	771.93
(N-CA) Trans-pacific ESRD Net.	616.99	672.57	732.68	760.87	807.23	864.19	936.53	975.17	1007.01	1041.69
(S-CA) Southern California Net.	523.32	569.66	619.51	690.09	732.15	762.05	833.01	906.90	956.73	972.84

Table B.21
Standard Errors for Adjusted December 31 Point Prevalence Rates
per Million Population of Reported ESRD Therapy
by Network Adjusted for Age, Race, and Sex

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	6.69	6.91	7.12	7.36	7.61	7.78	8.00	8.23	8.36	8.44
(NY) Net. of N.Y.	6.23	6.41	6.60	6.84	7.08	7.28	7.53	7.74	7.90	8.01
(NJ) Trans-Atlantic R. C.	9.75	10.05	10.46	10.82	11.14	11.31	11.67	11.95	12.14	12.22
(PA) ESRD Net. Org. #4	7.49	7.74	8.06	8.31	8.56	8.74	9.06	9.41	9.62	9.78
(VA) Mid Atlantic R. C.	7.56	7.82	8.07	8.36	8.60	8.80	8.91	9.18	9.48	9.64
(NC) Southeastern Kidney Council	6.92	7.17	7.39	7.59	7.81	7.97	8.18	8.36	8.48	8.52
(FL) ESRD Net. of Florida	7.51	7.69	7.91	8.10	8.28	8.37	8.41	8.55	8.72	8.74
(MS) Network 8	7.64	8.59	8.80	9.03	9.29	9.46	9.77	10.03	10.27	10.40
(IN) Tri-state R. N.	5.50	5.73	5.92	6.09	6.30	6.47	6.57	6.83	7.02	7.12
(IL) Renal Net. of Illinois	7.69	7.87	8.19	8.49	8.72	8.99	9.32	9.63	9.83	9.95
(MN) Renal Net. of upper midwest	5.54	5.79	5.97	6.13	6.34	6.49	6.68	6.84	7.01	7.11
(MD) ESRD net. #12	6.89	7.21	7.50	7.71	7.96	8.15	8.38	8.60	8.78	8.95
(OK) ESRD net. #13	8.36	8.73	9.09	9.36	9.61	9.90	10.26	10.62	10.79	11.02
(TX) Net. of Texas	6.39	6.59	6.82	6.97	7.12	7.24	7.40	7.50	7.62	7.65
(CO) Inter-mountain ESRD net.	6.93	7.18	7.29	7.42	7.51	7.52	7.57	7.65	7.66	7.69
(WA) Northwest Renal Net.	7.09	7.33	7.50	7.60	7.61	7.71	7.94	8.15	8.16	8.14
(N-CA) Trans-pacific ESRD Net.	7.82	8.03	8.26	8.08	8.21	8.41	8.67	8.76	8.79	8.83
(S-CA) Southern California Net.	5.49	5.64	5.82	6.16	6.27	6.34	6.58	6.81	6.93	6.91

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Rates per million based on the December 31, 1996 U.S. resident population by state for five-year age groups, sex, and White/non-White race groups.

Table B.22
December 31 Point Prevalence Counts
of Reported ESRD Therapy
by Age, Sex, and Race

1992-1994

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	5801	1636	219	115	7771	4073	1052	224	89	5438	9874	2688	443	204	13209
20-44	71112	34624	3438	1186	110360	52009	23054	2977	935	78975	123121	57678	6415	2121	189335
45-64	82595	46824	4245	2331	135995	63678	42227	3746	2238	111889	146273	89051	7991	4569	247884
65-74	48169	17511	2050	693	68423	43024	26373	2313	1205	72915	91193	43884	4363	1898	141338
75 plus	30248	7428	1137	277	39090	25232	12815	1222	416	39685	55480	20243	2359	693	78775
All Age	237925	108023	11089	4602	361639	188016	105521	10482	4883	308902	425941	213544	21571	9485	670541

1995-1997

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	6721	2100	250	105	9176	4533	1300	284	105	6222	11254	3400	534	210	15398
20-44	79184	41533	4146	1575	126438	57145	29720	3805	1299	91969	136329	71253	7951	2874	218407
45-64	108206	63106	6226	3267	180805	81086	54728	5468	3176	144458	189292	117834	11694	6443	325263
65-74	59985	22307	2932	1036	86260	52137	33175	3318	1617	90247	112122	55482	6250	2653	176507
75 plus	42819	10161	1994	364	55338	35414	17471	2112	671	55668	78233	27632	4106	1035	111006
All Age	296915	139207	15548	6347	458017	230315	136394	14987	6868	388564	527230	275601	30535	13215	846581

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31, 1996. Includes Medicare patients only.

Table B.23
December 31 Point Prevalence Rates per Million Population
of Reported ESRD Therapy
Specific Rates by Sex, Race, Age and Rates Adjusted for Age, Race, and Sex

1992-1994

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	64	93	51	89	47	62	54	71	56	80	55	84	69	51	60
20-44	562	1856	604	893	420	1116	493	711	481	1527	555	831	735	508	618
45-64	1303	6872	1984	4865	957	4988	1525	4307	1167	6224	1882	5054	2148	1599	1865
65-74	2173	8838	4121	6332	1560	9456	3499	8939	1865	9164	3831	7568	3134	2697	2913
75 plus	2165	6691	4312	4575	1010	6072	3590	4255	1469	5896	3643	4057	2632	1654	2133
All Age	750	2343	860	1405	571	2065	770	1468	659	2197	814	1437	953	778	863
Age Adj	773	3190	1202	2105	535	2481	968	2071	643	2827	1074	2094	1041	746	880

1995-1997

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	72	116	52	78	51	74	62	80	62	95	60	79	77	55	66
20-44	631	2177	682	1148	466	1413	584	966	528	1794	632	1085	819	580	696
45-64	1577	8303	2423	6155	1133	5793	1854	5516	1422	7554	2344	6466	2648	1920	2272
65-74	2710	10833	5226	8885	1927	11585	4288	11382	2318	11271	4805	10094	3904	3331	3614
75 plus	2789	8477	6235	5052	1340	7825	4830	5857	1926	7583	5208	5007	3413	2195	2792
All Age	913	2897	1086	1849	685	2566	982	1973	797	2723	1032	1911	1171	952	1059
Age Adj	929	3855	1515	2687	635	3033	1209	2709	767	3435	1345	2714	1254	896	1059

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996,

U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.24
Standard Errors for Adjusted December 31 Point Prevalence Rates per Million Population
of Reported ESRD Therapy
by Sex, Race, and Age
Adjusted for Age, Race, and Sex

1992-1994

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	0.8	2.3	3.4	8.3	0.7	1.9	3.6	7.5	0.6	1.5	2.6	5.9	0.8	0.7	0.5
20-44	2.1	10.0	10.3	25.9	1.8	7.4	9.0	23.3	1.4	6.4	7.0	18.1	2.2	1.8	1.4
45-64	4.5	31.8	30.5	100.8	3.8	24.3	24.9	91.0	3.1	21.3	21.9	77.2	6.1	4.9	3.9
65-74	9.9	66.8	91.0	240.5	7.5	58.2	72.8	257.5	6.2	44.7	59.0	175.7	12.6	10.3	8.1
75 plus	12.4	77.6	127.9	274.9	6.4	53.6	102.7	208.6	6.8	45.5	80.9	164.2	15.1	9.1	8.7
Age Adj	1.6	10.1	12.3	33.0	1.2	7.7	10.0	30.4	1.0	6.2	7.8	22.3	1.7	1.3	1.1

1995-1997

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	0.9	2.5	3.3	7.6	0.8	2.1	3.7	7.9	0.6	1.6	2.6	5.5	0.8	0.7	0.5
20-44	2.2	10.7	10.6	28.9	2.0	8.2	9.5	26.8	1.4	6.7	7.1	20.3	2.3	1.9	1.5
45-64	4.8	33.1	30.7	107.7	4.0	24.8	25.1	97.9	3.3	22.8	22.7	83.7	6.5	5.2	4.1
65-74	11.1	72.5	96.5	276.0	8.4	63.6	74.4	283.1	7.0	48.8	61.9	197.7	13.8	11.4	8.9
75 plus	13.5	84.1	139.6	264.8	7.1	59.2	105.1	226.1	7.5	50.0	87.2	163.4	16.4	10.1	9.5
Age Adj	1.7	10.7	13.1	35.5	1.3	8.3	10.3	33.5	1.1	6.7	8.1	24.4	1.9	1.4	1.2

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.25
December 31 Point Prevalence Counts
of Reported ESRD Therapy
by Age, Sex, Race, and Primary Disease Causing ESRD
1992-1994

Diabetes

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	12	*	*	*	25	25	16	*	*	44	37	23	*	*	69
20-44	19285	3833	367	316	23801	14423	3699	293	272	18687	33708	7532	660	588	42488
45-64	26517	13131	1401	1430	42479	21955	17147	1127	1571	41800	48472	30278	2528	3001	84279
65-74	13160	5545	799	382	19886	16424	11875	1066	883	30248	29584	17420	1865	1265	50134
75 plus	4450	1651	290	97	6488	5904	3957	392	225	10478	10354	5608	682	322	16966
All Age	63424	24167	2861	2227	92679	58731	36694	2879	2953	101257	122155	60861	5740	5180	193936

Hypertension

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	104	104	*	10	220	143	62	*	*	219	247	166	10	16	439
20-44	6316	14140	589	152	21197	3560	6223	415	99	10297	9876	20363	1004	251	31494
45-64	13325	21684	843	285	36137	8419	14478	718	188	23803	21744	36162	1561	473	59940
65-74	15500	7930	580	140	24150	10273	10030	540	120	20963	25773	17960	1120	260	45113
75 plus	14078	3957	496	73	18604	10316	6625	478	103	17522	24394	10582	974	176	36126
All Age	49323	47815	2510	660	100308	32711	37418	2159	516	72804	82034	85233	4669	1176	173112

Glomeruloneph.

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	1361	596	63	27	2047	1304	446	89	46	1885	2665	1042	152	73	3932
20-44	21701	9351	1610	383	33045	13817	5890	1258	274	21239	35518	15241	2868	657	54284
45-64	18815	5330	1195	330	25670	10692	3841	937	222	15692	29507	9171	2132	552	41362
65-74	7879	1227	330	73	9509	5019	1299	287	52	6657	12898	2526	617	125	16166
75 plus	4118	426	142	31	4717	3074	659	146	29	3908	7192	1085	288	60	8625
All Age	53874	16930	3340	844	74988	33906	12135	2717	623	49381	87780	29065	6057	1467	124369

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

* Values for cells with fewer than 10 patients are suppressed.

Table B.25(Continued)
 December 31 Point Prevalence Counts
 of Reported ESRD Therapy
 by Age, Sex, Race, and Primary Disease Causing ESRD

1992-1994

Cystic Kidney

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	324	34	*	10	372	268	32	19	*	322	592	66	23	13	694
20-44	2636	305	83	32	3056	1893	360	52	29	2334	4529	665	135	61	5390
45-64	8834	1006	215	70	10125	7965	1211	178	64	9418	16799	2217	393	134	19543
65-74	2354	276	76	*	2715	3086	300	70	15	3471	5440	576	146	24	6186
75 plus	712	95	15	*	827	783	97	13	*	897	1495	192	28	*	1724
All Age	14860	1716	393	126	17095	13995	2000	332	115	16442	28855	3716	725	241	33537

Other Urologic

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	640	160	34	10	844	235	18	*	*	258	875	178	37	12	1102
20-44	2084	353	56	28	2521	1429	157	37	27	1650	3513	510	93	55	4171
45-64	1189	258	48	14	1509	1083	223	50	*	1363	2272	481	98	21	2872
65-74	1149	258	40	10	1457	608	145	28	*	789	1757	403	68	18	2246
75 plus	1189	230	39	13	1471	426	71	24	*	522	1615	301	63	14	1993
All Age	6251	1259	217	75	7802	3781	614	142	45	4582	10032	1873	359	120	12384

Other Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	2642	533	88	46	3309	1533	364	71	24	1992	4175	897	159	70	5301
20-44	11485	3803	379	155	15822	10879	5067	639	147	16732	22364	8870	1018	302	32554
45-64	7021	2322	221	102	9666	8136	2675	442	91	11344	15157	4997	663	193	21010
65-74	4157	847	93	34	5131	4289	933	165	56	5443	8446	1780	258	90	10574
75 plus	2891	471	71	28	3461	2332	477	73	27	2909	5223	948	144	55	6370
All Age	28196	7976	852	365	37389	27169	9516	1390	345	38420	55365	17492	2242	710	75809

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 * Values for cells with fewer than 10 patients are suppressed.

Table B.25(Continued)
December 31 Point Prevalence Counts
of Reported ESRD Therapy
by Age, Sex, Race, and Primary Disease Causing ESRD

1992-1994

Unknown Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	501	136	16	*	662	377	69	26	*	478	878	205	42	15	1140
20-44	4938	2060	286	102	7386	3739	1180	229	62	5210	8677	3240	515	164	12596
45-64	4090	1866	259	72	6287	3208	1517	252	68	5045	7298	3383	511	140	11332
65-74	2679	762	107	37	3585	2091	883	128	45	3147	4770	1645	235	82	6732
75 plus	2078	360	74	29	2541	1680	518	75	17	2290	3758	878	149	46	4831
All Age	14286	5184	742	249	20461	11095	4167	710	198	16170	25381	9351	1452	447	36631

Missing Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	217	66	*	*	292	188	45	*	0	240	405	111	15	*	532
20-44	2667	779	68	18	3532	2269	478	54	25	2826	4936	1257	122	43	6358
45-64	2804	1227	63	28	4122	2220	1135	42	27	3424	5024	2362	105	55	7546
65-74	1291	666	25	*	1990	1234	908	29	26	2197	2525	1574	54	34	4187
75 plus	732	238	10	*	981	717	411	21	10	1159	1449	649	31	11	2140
All Age	7711	2976	174	56	10917	6628	2977	153	88	9846	14339	5953	327	144	20763

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

* Values for cells with fewer than 10 patients are suppressed.

Table B.25(Continued)
 December 31 Point Prevalence Counts
 of Reported ESRD Therapy
 by Age, Sex, Race, and Primary Disease Causing ESRD

1995-1997

Diabetes

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	30	19	*	*	55	25	26	*	0	54	55	45	*	*	109
20-44	21652	4969	439	388	27448	15736	5052	378	390	21556	37388	10021	817	778	49004
45-64	39027	19326	2169	2063	62585	31330	24091	1739	2221	59381	70357	43417	3908	4284	121966
65-74	19912	8502	1246	669	30329	22766	16865	1661	1225	42517	42678	25367	2907	1894	72846
75 plus	8380	2794	625	145	11944	10077	6579	840	391	17887	18457	9373	1465	536	29831
All Age	89001	35610	4482	3268	132361	79934	52613	4621	4227	141395	168935	88223	9103	7495	273756

Hypertension

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	102	95	0	*	203	130	64	*	*	210	232	159	*	14	413
20-44	7195	16334	681	238	24448	3912	7930	489	149	12480	11107	24264	1170	387	36928
45-64	16182	27554	1236	426	45398	9529	17386	1071	304	28290	25711	44940	2307	730	73688
65-74	17065	9399	792	157	27413	11097	11494	758	170	23519	28162	20893	1550	327	50932
75 plus	18458	5169	775	85	24487	13676	8214	735	166	22791	32134	13383	1510	251	47278
All Age	59002	58551	3484	912	121949	38344	45088	3061	797	87290	97346	103639	6545	1709	209239

Glomeruloneph.

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	1467	685	83	32	2267	1394	481	111	46	2032	2861	1166	194	78	4299
20-44	23685	10869	1957	471	36982	14993	7344	1678	394	24409	38678	18213	3635	865	61391
45-64	23195	7645	1657	397	32894	13194	5129	1347	327	19997	36389	12774	3004	724	52891
65-74	9083	1493	471	80	11127	5705	1532	370	83	7690	14788	3025	841	163	18817
75 plus	5604	599	269	58	6530	3850	806	239	40	4935	9454	1405	508	98	11465
All Age	63034	21291	4437	1038	89800	39136	15292	3745	890	59063	102170	36583	8182	1928	148863

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 * Values for cells with fewer than 10 patients are suppressed.

Table B.25(Continued)
December 31 Point Prevalence Counts
of Reported ESRD Therapy
by Age, Sex, Race, and Primary Disease Causing ESRD

1995-1997

Cystic Kidney

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	354	51	*	11	425	319	56	25	*	403	673	107	34	14	828
20-44	2867	375	80	41	3363	2100	437	75	30	2642	4967	812	155	71	6005
45-64	10751	1273	312	87	12423	9216	1450	218	81	10965	19967	2723	530	168	23388
65-74	3059	329	81	13	3482	3514	421	83	14	4032	6573	750	164	27	7514
75 plus	895	131	34	*	1062	1130	155	31	*	1323	2025	286	65	*	2385
All Age	17926	2159	516	154	20755	16279	2519	432	135	19365	34205	4678	948	289	40120

Other Urologic

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	682	191	25	*	904	300	29	*	*	338	982	220	30	10	1242
20-44	2620	445	88	47	3200	1956	227	63	34	2280	4576	672	151	81	5480
45-64	1828	364	78	22	2292	1638	277	89	*	2011	3466	641	167	29	4303
65-74	1484	334	42	14	1874	787	156	55	*	1004	2271	490	97	20	2878
75 plus	1723	241	55	22	2041	608	107	31	*	752	2331	348	86	28	2793
All Age	8337	1575	288	111	10311	5289	796	243	57	6385	13626	2371	531	168	16696

Other Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	3258	787	106	36	4187	1700	437	97	38	2272	4958	1224	203	74	6459
20-44	13147	5150	457	240	18994	12172	6696	775	209	19852	25319	11846	1232	449	38846
45-64	9449	3389	303	159	13300	10306	3767	598	137	14808	19755	7156	901	296	28108
65-74	5465	938	136	53	6592	5122	1130	194	64	6510	10587	2068	330	117	13102
75 plus	4312	591	103	31	5037	3462	672	101	29	4264	7774	1263	204	60	9301
All Age	35631	10855	1105	519	48110	32762	12702	1765	477	47706	68393	23557	2870	996	95816

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

* Values for cells with fewer than 10 patients are suppressed.

Table B.25(Continued)
 December 31 Point Prevalence Counts
 of Reported ESRD Therapy
 by Age, Sex, Race, and Primary Disease Causing ESRD

1995-1997

Unknown Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	458	165	12	*	643	397	107	20	*	530	855	272	32	14	1173
20-44	5233	2322	335	121	8011	3859	1341	272	71	5543	9092	3663	607	192	13554
45-64	4741	2174	345	83	7343	3611	1694	329	81	5715	8352	3868	674	164	13058
65-74	2673	803	125	45	3646	2146	887	159	37	3229	4819	1690	284	82	6875
75 plus	2661	410	116	19	3206	2005	611	129	29	2774	4666	1021	245	48	5980
All Age	15766	5874	933	276	22849	12018	4640	909	224	17791	27784	10514	1842	500	40640

Missing Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	370	107	12	*	492	268	100	15	0	383	638	207	27	*	875
20-44	2785	1069	109	29	3992	2417	693	75	22	3207	5202	1762	184	51	7199
45-64	3033	1381	126	30	4570	2262	934	77	18	3291	5295	2315	203	48	7861
65-74	1244	509	39	*	1797	1000	690	38	18	1746	2244	1199	77	23	3543
75 plus	786	226	17	*	1031	606	327	*	*	942	1392	553	23	*	1973
All Age	8218	3292	303	69	11882	6553	2744	211	61	9569	14771	6036	514	130	21451

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

* Values for cells with fewer than 10 patients are suppressed.

Table B.26
December 31 Point Prevalence Rates per Ten Million Population of Reported ESRD Therapy
by Primary Disease Causing ESRD
Specific Rates by Sex, Race, and Age
and Rates Adjusted for Age, Race, and Sex

1992-1994

Diabetes

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
20-44	1523	2055	644	2378	1163	1791	486	2068	1298	2006	578	2390	1551	1197	1370
45-64	4183	19272	6548	29848	3301	20254	4587	30232	3892	21584	6391	34017	6796	6187	6488
65-74	5938	27986	16061	34905	5955	42576	16127	65504	5927	35267	16080	49718	9297	11450	10422
75 plus	3184	14871	10997	16021	2363	18750	11515	23016	2390	14691	9773	17215	4275	4420	4357
All Age	2030	7569	3376	10586	1663	8839	2900	13056	1839	8291	3132	11999	2643	2429	2542
Age Adj	2030	7569	3376	10586	1663	8839	2900	13056	1839	8291	3132	11999	2643	2429	2542

Hypertension

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	11	59	*	77	17	36	*	*	15	50	13	64	18	20	19
20-44	499	7580	1034	1144	287	3013	688	753	384	5509	877	993	1473	658	1048
45-64	2102	31825	3940	5949	1266	17101	2922	3618	1793	25380	3748	5127	6254	3565	4855
65-74	6994	40023	11659	12793	3725	35961	8170	8902	5384	38250	10046	10957	11525	8081	9765
75 plus	10074	35641	18809	12057	4129	31392	14041	10536	6747	31614	15907	11183	13020	7640	10276
All Age	1680	14532	3149	3340	868	9035	2250	2313	1215	11689	2637	2782	3048	1697	2291
Age Adj	1680	14532	3149	3340	868	9035	2250	2313	1215	11689	2637	2782	3048	1697	2291

Glomeruloneph.

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	149	340	147	208	151	261	216	365	155	313	191	307	179	175	177
20-44	1714	5013	2827	2883	1115	2851	2085	2084	1390	3989	2478	2539	2185	1371	1766
45-64	2968	7823	5585	6888	1607	4537	3814	4272	2298	6061	4672	5516	3722	2093	2887
65-74	3555	6193	6633	6670	1820	4657	4342	3858	2671	5395	5494	5124	4032	2289	3142
75 plus	2947	3837	5385	5120	1230	3123	4289	2967	1897	3151	4312	3533	2862	1485	2161
All Age	1722	4354	3078	3389	997	2622	2198	2240	1336	3469	2612	2783	2084	1227	1628
Age Adj	1722	4354	3078	3389	997	2622	2198	2240	1336	3469	2612	2783	2084	1227	1628

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.26(Continued)
 December 31 Point Prevalence Rates per Ten Million Population of Reported ESRD Therapy
 by Primary Disease Causing ESRD
 Specific Rates by Sex, Race, and Age
 and Rates Adjusted for Age, Race, and Sex

1992-1994

Cystic Kidney

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	36	19	*	77	31	19	46	*	34	19	28	50	33	30	32
20-44	208	164	146	241	153	174	86	221	179	178	121	248	203	153	177
45-64	1394	1476	1005	1461	1197	1430	724	1232	1341	1513	923	1394	1437	1263	1348
65-74	1062	1393	1528	*	1119	1076	1059	1113	1081	1206	1279	932	1104	1103	1102
75 plus	510	856	569	*	313	460	382	*	371	580	356	*	498	301	397
All Age	479	521	408	527	406	469	291	452	441	491	346	489	479	409	442
Age Adj	479	521	408	527	406	469	291	452	441	491	346	489	479	409	442

Other Urologic

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	70	91	79	77	27	11	*	*	49	51	44	46	74	25	49
20-44	165	189	98	211	115	76	61	205	140	132	79	201	166	109	137
45-64	188	379	224	292	163	263	203	*	181	347	224	242	228	182	204
65-74	518	1302	804	914	220	520	424	*	372	923	649	716	647	271	454
75 plus	851	2072	1479	2147	170	336	705	*	483	1202	956	1086	1018	193	595
All Age	206	388	246	345	110	143	138	153	152	249	186	230	223	113	161
Age Adj	206	388	246	345	110	143	138	153	152	249	186	230	223	113	161

Other Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	290	304	205	354	178	213	172	191	237	264	199	287	294	188	240
20-44	907	2039	666	1167	878	2453	1059	1118	884	2269	870	1140	1045	1077	1062
45-64	1108	3408	1033	2129	1223	3160	1799	1751	1191	3306	1456	2103	1438	1514	1476
65-74	1876	4275	1869	3107	1555	3345	2496	4154	1715	3832	2224	3646	2208	1838	2018
75 plus	2069	4242	2692	4625	933	2260	2144	2762	1393	3099	2176	3424	2248	1087	1654
All Age	902	2146	816	1469	798	2026	1126	1312	841	2066	971	1381	1035	950	984
Age Adj	902	2146	816	1469	798	2026	1126	1312	841	2066	971	1381	1035	950	984

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.26(Continued)
December 31 Point Prevalence Rates per Ten Million Population of Reported ESRD Therapy
by Primary Disease Causing ESRD
Specific Rates by Sex, Race, and Age
and Rates Adjusted for Age, Race, and Sex

1992-1994

Unknown Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	55	77	37	*	44	40	63	*	50	61	54	62	59	45	52
20-44	390	1104	502	768	302	571	380	471	341	853	443	629	490	338	411
45-64	645	2739	1211	1503	482	1792	1026	1309	580	2354	1164	1547	972	704	834
65-74	1209	3846	2151	3381	758	3166	1936	3338	987	3478	2064	3292	1602	1132	1362
75 plus	1487	3243	2806	4790	672	2454	2203	1739	1029	2740	2412	3102	1719	926	1315
All Age	466	1481	772	1148	317	961	638	805	383	1210	697	957	586	392	479
Age Adj	466	1481	772	1148	317	961	638	805	383	1210	697	957	586	392	479

Missing Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	24	38	*	*	22	26	*	0	23	33	19	*	26	22	24
20-44	211	418	119	135	183	231	90	190	193	333	107	169	233	183	207
45-64	442	1801	294	584	334	1341	171	520	393	1695	238	594	631	481	553
65-74	582	3361	503	*	447	3255	439	1929	512	3289	471	1294	931	809	869
75 plus	524	2144	379	*	287	1947	617	1023	381	1878	535	591	675	485	578
All Age	249	905	172	243	192	710	142	374	218	804	159	315	311	239	272
Age Adj	249	905	172	243	192	710	142	374	218	804	159	315	311	239	272

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.26(Continued)
 December 31 Point Prevalence Rates per Ten Million Population of Reported ESRD Therapy
 by Primary Disease Causing ESRD
 Specific Rates by Sex, Race, and Age
 and Rates Adjusted for Age, Race, and Sex

1995-1997

Diabetes

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	10	*	*	*	15	*	0	*	13	*	*	*	*	*
20-44	1724	2605	722	2829	1284	2402	580	2901	1408	2513	653	3021	1733	1344	1535
45-64	5687	25428	8442	38866	4377	25500	5896	38577	5357	28915	8456	44123	9376	8227	8792
65-74	8996	41289	22210	57376	8414	58896	21464	86231	8700	50263	22001	71332	13974	15977	15029
75 plus	5458	23309	19543	20126	3813	29466	19212	34129	4044	23305	17533	24563	7184	7136	7173
All Age	2743	10554	4752	14533	2186	12057	4071	17400	2449	11419	4393	16191	3604	3237	3421
Age Adj	2743	10554	4752	14533	2186	12057	4071	17400	2449	11419	4393	16191	3604	3237	3421

Hypertension

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	11	52	0	*	15	36	*	*	13	45	*	54	16	18	17
20-44	573	8562	1120	1735	319	3770	750	1108	426	6166	933	1468	1614	764	1172
45-64	2358	36254	4811	8026	1331	18403	3631	5280	2013	28789	4707	7061	7231	3932	5516
65-74	7710	45646	14117	13465	4101	40139	9795	11967	5929	43286	12198	12890	12946	9039	10948
75 plus	12023	43122	24233	11798	5175	36789	16810	14489	8286	38132	20158	12419	15817	9399	12541
All Age	1929	16611	3851	4017	983	10253	2726	3256	1387	13310	3210	3646	3492	1933	2617
Age Adj	1929	16611	3851	4017	983	10253	2726	3256	1387	13310	3210	3646	3492	1933	2617

Glomeruloneph.

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	157	378	173	239	157	274	242	352	158	329	219	298	188	179	183
20-44	1886	5697	3218	3434	1223	3491	2575	2931	1506	4582	2888	3226	2393	1549	1959
45-64	3380	10059	6449	7479	1843	5429	4567	5680	2642	7604	5522	6667	4418	2447	3406
65-74	4104	7251	8395	6861	2108	5350	4781	5843	3090	6304	6641	6222	4699	2655	3655
75 plus	3650	4997	8411	8050	1457	3610	5466	3491	2359	3946	6431	4932	3721	1786	2734
All Age	1944	5174	3710	3915	1118	3118	2652	3028	1503	4116	3135	3435	2385	1406	1862
Age Adj	1944	5174	3710	3915	1118	3118	2652	3028	1503	4116	3135	3435	2385	1406	1862

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.26(Continued)
December 31 Point Prevalence Rates per Ten Million Population of Reported ESRD Therapy
by Primary Disease Causing ESRD
Specific Rates by Sex, Race, and Age
and Rates Adjusted for Age, Race, and Sex

1995-1997

Cystic Kidney

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	38	28	*	82	36	32	54	*	37	30	39	50	36	36	36
20-44	228	197	132	299	171	208	115	223	191	204	125	271	214	169	191
45-64	1567	1675	1214	1639	1287	1535	739	1407	1495	1700	1047	1647	1635	1381	1505
65-74	1382	1598	1444	1115	1299	1470	1073	985	1332	1527	1250	1016	1401	1304	1351
75 plus	583	1093	1063	*	428	694	709	*	446	817	758	*	586	424	503
All Age	546	608	471	580	453	552	330	496	498	576	395	540	548	459	502
Age Adj	546	608	471	580	453	552	330	496	498	576	395	540	548	459	502

Other Urologic

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	73	105	52	*	34	17	*	*	53	60	32	36	76	31	53
20-44	209	233	145	343	160	108	97	253	183	170	120	294	210	150	180
45-64	266	479	304	414	229	293	302	*	260	417	351	297	320	249	283
65-74	670	1622	749	1201	291	545	711	*	482	1089	731	830	812	340	570
75 plus	1122	2011	1720	3054	230	479	709	*	646	1249	1249	1824	1264	266	754
All Age	266	452	288	495	151	173	196	192	200	295	234	317	284	152	209
Age Adj	266	452	288	495	151	173	196	192	200	295	234	317	284	152	209

Other Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	348	434	221	268	192	249	211	291	270	341	226	281	355	203	277
20-44	1047	2699	752	1750	993	3183	1189	1555	1004	2937	976	1664	1245	1262	1255
45-64	1377	4459	1179	2995	1440	3987	2028	2380	1453	4219	1654	2801	1825	1820	1822
65-74	2469	4555	2424	4545	1893	3946	2507	4505	2183	4292	2491	4528	2773	2202	2482
75 plus	2809	4930	3221	4303	1310	3010	2310	2531	1943	3800	2596	3226	2969	1489	2213
All Age	1111	2701	955	1959	935	2567	1243	1643	1010	2617	1093	1782	1286	1136	1198
Age Adj	1111	2701	955	1959	935	2567	1243	1643	1010	2617	1093	1782	1286	1136	1198

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1,

1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.26(Continued)
 December 31 Point Prevalence Rates per Ten Million Population of Reported ESRD Therapy
 by Primary Disease Causing ESRD
 Specific Rates by Sex, Race, and Age
 and Rates Adjusted for Age, Race, and Sex

1995-1997

Unknown Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	49	91	25	*	45	61	44	*	47	77	37	53	54	47	51	
20-44	417	1217	551	882	315	638	417	528	356	924	482	714	521	354	435	
45-64	691	2860	1343	1564	504	1793	1115	1407	620	2413	1322	1585	1038	732	880	
65-74	1208	3900	2228	3859	793	3098	2055	2605	1001	3524	2155	3263	1624	1151	1382	
75 plus	1733	3420	3627	2637	759	2737	2950	2531	1206	2970	3048	2452	1952	1083	1509	
All Age	497	1564	865	1113	335	1008	720	845	406	1276	787	979	624	415	508	
Age Adj	497	1564	865	1113	335	1008	720	845	406	1276	787	979	624	415	508	

Missing Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	39	59	25	*	30	57	33	0	35	58	29	*	41	34	37	
20-44	222	560	179	211	197	329	115	164	202	442	147	189	258	204	230	
45-64	442	1817	490	565	316	989	261	313	380	1483	381	476	634	413	520	
65-74	562	2472	695	*	370	2410	491	1267	464	2422	584	855	807	636	720	
75 plus	512	1885	532	*	229	1465	*	*	335	1606	311	*	630	365	494	
All Age	253	891	255	254	187	598	150	235	217	738	198	246	318	226	268	
Age Adj	253	891	255	254	187	598	150	235	217	738	198	246	318	226	268	

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.27
Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population of Reported ESRD Therapy by Primary Disease Causing ESRD by Sex, Race, and Age Adjusted for Age, Race, and Sex

1992-1994

Diabetes

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	0.4	*	*	*	0.6	2.3	*	*	0.4	1.5	*	*	0.4	0.6	0.4
20-44	11.0	33.2	33.6	133.8	9.7	29.4	28.4	125.4	7.1	23.3	22.6	99.0	10.1	8.8	6.7
45-64	25.7	168.2	174.9	789.3	22.3	154.7	136.6	762.7	17.9	126.5	131.2	639.3	34.3	30.9	23.0
65-74	51.8	375.8	568.2	1785.9	46.5	390.7	493.9	2204.4	34.7	272.5	378.8	1412.6	69.3	68.1	48.6
75 plus	47.7	366.0	645.8	1626.7	30.8	298.1	581.6	1534.4	25.3	212.7	401.9	1005.2	60.4	47.5	38.2
Age Adj	8.1	49.8	66.5	232.9	6.9	46.4	56.3	244.3	5.3	34.0	43.3	171.0	8.7	7.7	5.8

Hypertension

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	1.1	5.8	*	24.4	1.4	4.6	*	*	0.9	3.9	4.2	16.0	1.3	1.4	0.9
20-44	6.3	63.7	42.6	92.8	4.8	38.2	33.8	75.7	3.9	38.8	27.8	63.0	10.2	6.5	5.9
45-64	18.2	216.1	135.7	352.4	13.8	142.1	109.1	263.9	12.3	136.6	98.4	245.4	34.0	23.5	20.4
65-74	56.2	449.4	484.1	1081.2	36.7	359.1	351.6	812.6	33.8	291.5	305.5	687.7	77.7	57.5	47.9
75 plus	84.9	566.6	844.6	1411.2	40.6	385.7	642.2	1038.2	47.4	337.3	550.3	905.8	108.1	63.2	61.7
Age Adj	7.7	68.8	68.4	139.8	4.8	47.0	51.5	104.9	4.2	40.7	41.5	84.8	9.7	6.3	5.5

Glomeruloneph.

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	4.0	13.9	18.5	40.0	4.2	12.4	22.9	53.9	3.0	9.7	15.6	36.0	4.0	4.1	2.8
20-44	11.6	51.8	70.5	147.3	9.5	37.2	58.8	125.9	7.4	32.5	46.4	99.6	12.1	9.4	7.6
45-64	21.6	107.1	161.6	379.2	15.5	73.2	124.6	286.7	13.6	64.9	105.3	243.3	24.0	17.1	14.6
65-74	40.1	176.8	365.2	780.7	25.7	129.2	256.3	534.9	23.7	109.7	224.8	464.0	43.0	28.9	25.7
75 plus	45.9	185.9	451.9	919.6	22.2	121.6	354.9	550.9	24.4	104.4	274.2	476.9	46.7	26.3	26.5
Age Adj	7.5	34.6	56.9	124.0	5.4	24.1	44.1	92.7	4.5	20.8	35.4	75.9	7.7	5.5	4.6

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.27(Continued)
 Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population
 of Reported ESRD Therapy by Primary Disease Causing ESRD
 by Sex, Race, and Age
 Adjusted for Age, Race, and Sex

1992-1994

Cystic Kidney

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	2.0	3.3	*	24.4	1.9	3.3	10.6	*	1.4	2.4	5.9	13.8	1.7	1.7	1.2	
20-44	4.1	9.4	16.0	42.6	3.5	9.2	12.0	41.0	2.7	7.0	10.4	31.9	3.7	3.2	2.4	
45-64	14.8	46.6	68.5	174.6	13.4	41.1	54.3	154.0	10.5	32.9	48.3	124.5	14.7	13.2	9.9	
65-74	21.9	83.8	175.2	*	20.1	62.1	126.6	287.3	14.7	51.3	107.8	191.9	21.9	19.1	14.5	
75 plus	19.1	87.8	146.9	*	11.2	46.7	105.9	*	10.5	46.1	70.8	*	19.2	10.8	10.8	
Age Adj	3.9	12.9	21.4	49.2	3.5	10.5	16.4	43.0	2.6	8.2	13.3	32.5	3.7	3.2	2.4	

Other Urologic

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	2.8	7.2	13.6	24.4	1.8	2.5	*	*	1.7	3.8	7.2	13.5	2.6	1.6	1.5	
20-44	3.6	10.1	13.1	39.8	3.0	6.1	10.1	39.5	2.4	5.9	8.2	27.1	3.3	2.7	2.1	
45-64	5.4	23.6	32.4	78.1	4.9	17.6	28.8	*	3.9	16.2	23.4	54.8	6.1	5.0	3.9	
65-74	15.3	81.1	127.1	289.0	8.9	43.2	80.1	*	8.9	47.0	79.9	170.6	17.7	10.0	10.0	
75 plus	24.7	136.6	236.8	595.5	8.3	39.9	143.9	*	13.2	75.3	126.9	315.2	30.1	9.5	15.4	
Age Adj	2.6	11.8	18.4	45.9	1.8	5.8	12.4	23.9	1.5	5.9	10.6	22.7	2.6	1.7	1.4	

Other Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	5.6	13.2	21.8	52.2	4.5	11.2	20.5	38.9	3.7	8.8	15.8	34.4	5.1	4.2	3.3	
20-44	8.5	33.1	34.2	93.7	8.4	34.5	41.9	92.2	5.9	24.2	27.3	65.9	8.3	8.4	5.9	
45-64	13.2	70.7	69.5	210.8	13.6	61.1	85.6	183.6	9.8	48.0	59.0	156.4	15.1	14.5	10.5	
65-74	29.1	146.9	193.8	532.8	23.7	109.5	194.3	555.1	18.8	93.0	141.0	388.8	32.1	25.6	20.4	
75 plus	38.5	195.5	319.5	874.0	19.3	103.5	251.0	531.5	21.2	110.8	196.6	494.1	43.2	22.2	23.9	
Age Adj	5.4	25.2	30.7	85.6	4.9	21.0	31.6	73.7	3.6	16.1	21.9	55.4	5.4	4.9	3.6	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.27(Continued)
 Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population
 of Reported ESRD Therapy by Primary Disease Causing ESRD
 by Sex, Race, and Age
 Adjusted for Age, Race, and Sex

1992-1994

Unknown Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	2.5	6.6	9.3	*	2.3	4.9	12.4	*	1.7	4.3	8.3	16.1	2.3	2.1	1.5
20-44	5.5	24.3	29.7	76.0	4.9	16.6	25.1	59.9	3.7	15.1	19.6	49.4	5.7	4.7	3.7
45-64	10.1	63.4	75.2	177.1	8.5	46.0	64.6	158.7	6.9	41.5	53.7	135.5	12.7	10.1	8.1
65-74	23.4	139.3	207.9	555.8	16.6	106.5	171.2	497.6	14.4	87.5	136.7	366.9	27.9	20.9	17.3
75 plus	32.6	170.9	326.2	889.5	16.4	107.8	254.4	421.8	18.5	102.0	212.7	485.9	38.8	21.4	21.8
Age Adj	3.9	21.5	31.0	80.1	3.0	15.0	25.4	59.3	2.4	12.8	19.6	47.9	4.1	3.1	2.5

Missing Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	1.6	4.6	*	*	1.6	3.9	*	0.0	1.2	3.1	4.8	*	1.5	1.5	1.0
20-44	4.1	15.0	14.5	31.9	3.8	10.6	12.2	38.0	2.8	9.4	9.7	25.8	3.9	3.4	2.6
45-64	8.4	51.4	37.1	110.4	7.1	39.8	26.4	100.0	5.6	35.6	24.1	83.4	10.2	8.4	6.6
65-74	16.2	130.2	100.5	*	12.7	108.0	81.5	378.3	10.2	84.7	65.1	225.8	21.9	17.8	14.0
75 plus	19.4	139.0	119.9	*	10.7	96.1	134.6	323.5	11.0	80.7	102.8	191.4	24.3	15.6	14.3
Age Adj	2.9	17.2	14.1	34.2	2.4	13.1	12.3	40.9	1.8	10.6	9.5	27.4	3.0	2.4	1.9

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is July 1,

1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.27(Continued)
 Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population
 of Reported ESRD Therapy by Primary Disease Causing ESRD
 by Sex, Race, and Age
 Adjusted for Age, Race, and Sex

1995-1997

Diabetes

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	0.6	2.4	*	*	0.6	2.9	*	0.0	0.4	1.9	*	*	0.6	0.6	0.4	
20-44	11.7	36.9	34.5	143.6	10.2	33.8	29.8	146.9	7.3	25.2	22.9	108.5	10.5	9.2	6.9	
45-64	28.8	182.9	181.3	855.7	24.7	164.3	141.4	818.6	20.7	142.9	140.2	698.5	39.3	34.7	26.1	
65-74	63.8	447.8	629.2	2218.3	55.8	453.5	526.6	2463.7	42.3	321.8	415.1	1652.6	83.6	79.6	57.7	
75 plus	59.6	441.0	781.7	1671.4	38.0	363.3	662.9	1726.0	31.9	261.0	492.6	1103.8	74.6	58.1	47.0	
Age Adj	9.2	57.3	74.9	263.2	7.8	52.8	61.8	272.4	6.0	38.9	48.0	191.9	10.0	8.6	6.5	

Hypertension

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	1.1	5.4	0.0	*	1.3	4.6	*	*	0.9	3.6	*	14.5	1.1	1.3	0.9	
20-44	6.8	67.0	42.9	112.5	5.1	42.3	33.9	90.8	4.1	39.7	27.3	74.8	10.4	6.9	6.1	
45-64	18.5	218.4	136.8	388.8	13.6	139.6	111.0	302.8	12.8	140.8	102.3	272.8	35.4	24.0	21.1	
65-74	59.0	470.8	501.6	1074.6	38.9	374.4	355.8	917.8	35.5	305.6	315.3	719.3	81.4	60.4	50.2	
75 plus	88.5	599.8	870.5	1279.7	44.2	405.9	620.1	1124.6	50.4	361.1	554.0	823.9	114.1	67.5	65.3	
Age Adj	8.0	71.2	70.2	141.0	5.1	48.6	51.6	118.4	4.4	42.0	42.1	91.7	10.1	6.6	5.7	

Glomeruloneph.

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	4.1	14.4	19.0	42.2	4.2	12.5	22.9	52.0	3.0	9.6	15.8	33.8	4.0	4.0	2.8	
20-44	12.3	54.6	72.7	158.2	10.0	40.7	62.9	147.7	7.7	34.0	48.0	110.0	12.5	10.0	7.9	
45-64	22.2	115.0	158.4	375.4	16.0	75.8	124.4	314.1	14.2	70.1	105.7	259.0	25.4	17.8	15.4	
65-74	43.1	187.6	386.8	767.1	27.9	136.7	248.6	641.3	25.5	117.0	233.1	491.6	46.1	31.0	27.5	
75 plus	48.8	204.2	512.8	1057.1	23.5	127.2	353.6	552.0	26.4	115.2	306.8	521.0	51.6	27.7	28.9	
Age Adj	7.8	36.6	59.4	129.0	5.7	25.4	44.8	104.3	4.7	21.9	36.3	81.3	8.0	5.8	4.8	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.27(Continued)
 Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population
 of Reported ESRD Therapy by Primary Disease Causing ESRD
 by Sex, Race, and Age
 Adjusted for Age, Race, and Sex

1995-1997

Cystic Kidney

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	2.0	3.9	*	24.7	2.0	4.3	10.9	*	1.4	2.9	6.7	13.4	1.8	1.8	1.3
20-44	4.3	10.2	14.7	46.7	3.7	9.9	13.3	40.7	2.7	7.2	10.0	32.3	3.7	3.3	2.5
45-64	15.1	46.9	68.8	175.7	13.4	40.3	50.1	156.3	10.8	33.7	47.4	132.1	15.2	13.5	10.1
65-74	25.0	88.1	160.4	309.2	21.9	71.7	117.7	263.4	16.5	56.9	99.4	197.6	24.4	20.8	16.0
75 plus	19.5	95.5	182.3	*	12.7	55.8	127.3	*	10.7	53.3	99.9	*	20.3	12.5	11.8
Age Adj	4.1	13.4	21.8	48.5	3.6	11.1	16.3	43.4	2.7	8.5	13.3	32.6	3.8	3.3	2.5

Other Urologic

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	2.8	7.6	10.4	*	2.0	3.1	*	*	1.7	4.1	5.9	11.3	2.5	1.7	1.5
20-44	4.1	11.1	15.4	50.0	3.6	7.2	12.2	43.4	2.7	6.6	9.8	32.8	3.7	3.2	2.4
45-64	6.2	25.1	34.4	88.4	5.7	17.6	32.0	*	4.5	17.1	28.2	56.9	7.0	5.7	4.5
65-74	17.4	88.8	115.5	320.9	10.4	43.6	95.8	*	10.2	50.2	75.5	187.1	19.4	11.0	11.0
75 plus	27.0	129.5	231.9	651.0	9.3	46.3	127.3	*	14.6	73.2	142.8	364.8	31.7	10.7	16.3
Age Adj	2.9	12.2	18.7	52.2	2.1	6.2	13.1	26.7	1.7	6.3	10.8	26.0	2.8	1.9	1.6

Other Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	6.1	15.5	21.5	44.7	4.7	11.9	21.4	47.2	3.8	9.8	15.9	32.8	5.5	4.3	3.5
20-44	9.1	37.6	35.2	112.9	9.0	38.9	42.7	107.5	6.3	27.0	27.9	78.7	9.1	9.0	6.4
45-64	14.2	76.6	67.8	237.6	14.2	65.0	82.9	203.3	10.6	52.0	57.9	170.4	16.5	15.4	11.3
65-74	33.4	148.7	207.9	624.4	26.4	117.4	180.0	563.1	21.3	96.5	139.4	422.6	35.3	27.9	22.3
75 plus	42.8	202.8	317.3	772.8	22.3	116.1	229.9	470.0	24.1	117.5	196.6	446.2	47.0	24.6	26.1
Age Adj	5.9	27.1	31.2	92.8	5.2	23.0	30.6	77.7	3.9	17.4	21.5	59.2	5.9	5.2	3.9

(CONTINUED)

Includes residents of 50 states and District of Columbia only.
 Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.
 Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.
 Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.
 The population base is the U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

Table B.27(Continued)
 Standard Errors for Adjusted December 31 Point Prevalence Rates per Ten Million Population
 of Reported ESRD Therapy by Primary Disease Causing ESRD
 by Sex, Race, and Age
 Adjusted for Age, Race, and Sex

1995-1997

Unknown Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	2.3	7.1	7.2	*	2.3	5.9	9.7	*	1.6	4.6	6.5	14.2	2.1	2.1	1.5
20-44	5.8	25.3	30.1	80.2	5.1	17.4	25.3	62.7	3.8	15.3	19.6	51.7	5.8	4.8	3.8
45-64	10.0	61.3	72.3	171.6	8.4	43.6	61.5	156.3	7.0	40.3	53.4	129.2	12.7	10.0	8.0
65-74	23.4	137.6	199.3	575.3	17.1	104.0	162.9	428.2	14.5	87.6	129.9	363.1	28.0	20.8	17.3
75 plus	33.6	168.9	336.8	605.0	16.9	110.7	259.8	470.0	19.3	101.3	208.4	367.5	38.6	22.5	22.1
Age Adj	4.0	21.3	30.6	71.8	3.1	14.9	25.0	58.2	2.4	12.7	19.5	45.9	4.2	3.1	2.5

Missing Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	2.1	5.7	7.2	*	1.8	5.7	8.4	0.0	1.4	4.1	5.6	*	1.9	1.7	1.3
20-44	4.2	17.1	17.2	39.3	4.0	12.5	13.3	34.9	2.8	10.6	10.9	26.5	4.1	3.6	2.7
45-64	8.0	48.9	43.7	103.2	6.6	32.3	29.8	73.7	5.4	32.1	28.1	71.8	9.9	7.4	6.1
65-74	15.9	109.6	111.3	*	11.7	91.7	79.7	298.6	9.8	71.4	67.8	179.5	19.8	15.6	12.5
75 plus	18.3	125.4	128.9	*	9.3	81.0	*	*	9.8	74.8	69.0	*	22.4	12.8	12.7
Age Adj	2.8	16.1	15.6	32.2	2.3	11.5	10.6	30.9	1.8	9.7	9.1	22.5	2.9	2.3	1.8

Includes residents of 50 states and District of Columbia only.

Patients alive on ESRD therapy and not lost to followup on December 31 of each year. Includes Medicare patients only.

Prevalent cases for December 31 of 1994, 1995, 1996, and 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from table. See tables B.6 and B.7 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on December 31 of each year. Standard population for adjustment is July 1, 1996, U.S. resident population. * Values for cells with fewer than 10 patients are suppressed.

